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ABSTRACT 
 
Neuronal histamine and its H3 receptor (H3R) regulate several physiological 
functions and are involved in the pathophysiology of various central nervous 
system disorders such as Parkinson’s disease, Alzheimer’s disease, Tourette 
syndrome and narcolepsy. The first H3R antagonist likely to enter the clinical 
use is pitolisant (Wakix®) in the treatment of narcolepsy. Studies conducted in 
experimental animals have also suggested a role for histamine and especially 
H3R in the effects of drugs of abuse. Furthermore, recent findings have 
demonstrated that brain histaminergic system might play a role in Tourette 
syndrome.  In this thesis, the main aim was to study how histamine and H3R 
regulate alcohol-related behaviors and symptoms associated with psychiatric 
disorders such as Tourette syndrome and schizophrenia. Furthermore, our goal 
was to investigate the underlying mechanisms in the observed behaviors. 
 
By using both wild type (WT) mice in different background strains and 
genetically modified mice, we studied whether histamine and H3R regulate the 
behavioral responses of alcohol. Three different H3R antagonists (ciproxifan, 
JNJ-10181457 and JNJ-39220675) were used in these studies and it was found 
that both pharmacological antagonism and genetic knockout of H3R (H3R KO) 
lead to diminished alcohol consumption and reward. By using histamine 
deficient histidine decarboxylase knockout (HDC KO) mice, we found that the 
lack of histamine does not alter alcohol consumption or reward but it is indeed 
required for the H3R-mediated alcohol reward inhibition.  We also found that 
H3R antagonist JNJ-39220675 inhibited the acute stimulation of amphetamine, 
but failed to inhibit the rewarding properties of amphetamine. This indicates 
that although H3R antagonists inhibit alcohol reward, they may not possess the 
same ability on psychostimulants, such as amphetamine. 
 
Sensorimotor gating is a neurological process in which an irrelevant sensory, 
cognitive or motor stimulus is suppressed and filtered out in order to focus 
attention to significant stimulus. It is impaired for instance in Tourette 
syndrome and schizophrenia and can be studied both in humans and animals by 
using a prepulse inhibition of the startle reflex (PPI) method. Here, we studied 
whether histamine, H1 receptor (H1R) and H3R regulate sensorimotor gating in 
three different gene knockout mice and found that H3R KO but not HDC KO or 
H1 receptor knockout (H1R KO) mice have impaired PPI indicating a 
deficiency in sensorimotor gating. The results from all behavioral studies of this 
work indicated that rather that histamine per se, H3R is an important modulator 
of several brain dysfunctions that are in major part regulated by the brain 
dopaminergic system. 
 
The findings obtained from the behavioral experiments led us to hypothesize 
that H3R interacts with the dopaminergic system. This was further studied on a 
molecular level using both radioactive in situ hybridization and semi-
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quantitative Western blotting.  We found that H3R KO mice displayed lower 
levels of D1 receptor mRNA in the striatum compared to control mice. In 
addition, we found that systemic administration of dopamine D1 and D2 
receptor agonists, SKF-38393 and quinpirole, respectively, induced an 
activation of extracellular signal-regulated kinase 1/2 (ERK1/2) in the striatum 
of the WT mice but failed to do so in H3R KO mice. 
 
Taken together, these findings demonstrate that H3R is an important regulator 
of both alcohol-related behaviors and sensorimotor gating. The mechanism by 
which H3R regulates these phenomena might involve the interaction between 
the striatal H3R and dopamine receptors. The results are import for 
understanding the role of H3R in the behavioral effects of alcohol and in brain 
dopaminergic regulation and provide preclinical evidence that H3R antagonists 
may serve as a novel approach to treat alcohol dependence. 
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ABSTRAKTI 
 
Aivojen histamiini ja H3-reseptori alkoholikäyttäytymisessä 
sekä dopaminergisessä säätelyssä 
 
Aivojen histamiini ja sen H3-reseptori säätelevät useita fysiologisia toimintoja, 
mutta ovat myös mukana erilaisten keskushermostohäiriöiden 
patofysiologiassa. Tällaisia ovat muun muassa Parkinsonin tauti, Alzheimerin 
tauti, Touretten syndrooma ja narkolepsia. Pitolisantti (Wakix®) on 
ensimmäinen todennäköisesti myös kliiniseen käyttöön tuleva H3-reseptorin 
antagonisti, joka on tarkoitettu narkolepsian oireiden hoitoon. Aikaisemmissa 
eläinkokeissa on havaittu että histamiini sekä H3-reseptori ovat myös osallisina 
riippuvuuskäyttäytymisessä. Lisäksi, tuoreessa julkaisussa havaittiin yhteys 
Touretten syndrooman ja aivojen histaminergisen järjestelmän välillä. Tämän 
väitöskirjan tavoitteena oli selvittää, miten histamiini ja H3-reseptori säätelevät 
alkoholikäyttäytymistä sekä muun muassa Touretten syndroomaan liittyvää 
käyttäytymistä. Lisäksi tavoitteena oli selvittää, mitkä molekyylitason 
mekanismit ovat näiden ilmiöiden takana.  
 
Käytimme tässä työssä usean eri taustakannan villityypin sekä geneettisesti 
muunneltuja hiiriä. Tutkimuksen ensimmäisissä osioissa tutkimme, kuinka H3-
reseptori säätelee alkoholikäyttäytymistä. Havaitsimme, että kolme H3-
reseptorin salpaajaa (siproksifaani, JNJ-10181457 ja JNJ-39220675) sekä H3-
reseptorin geenitoiminnan sammuttaminen vähensivät alkoholin kulutusta sekä 
sen aiheuttamaa mielihyvää. Histamiinin suhteen poistogeenisillä hiirillä ei 
havaittu eroja alkoholin kulutuksessa tai sen tuottamassa mielihyvässä 
kontrollihiiriin verrattuna. Kuitenkaan H3-reseptorin farmakologinen salpaus ei 
estänyt alkoholin tuottamaa mielihyvää histamiinin suhteen poistogeenisillä 
hiirillä, osoittaen että histamiinilla on estävä vaikutus alkoholin aiheuttamassa 
mielihyvässä. Havaitsimme myös, että H3-reseptorin antagonisti JNJ-39220675 
esti amfetamiinin aiheuttamaa liikeaktiivisuuden stimulaatioita, mutta ei 
mielihyvää. Vaikka H3-reseptorin farmakologinen salpaus estääkin alkoholin 
tuottamaa mielihyvää, tämä tutkimus osoittaa, että se ei välttämättä estä 
esimerkiksi psykostimulanttien aiheuttamaa mielihyvää. 
 
Aivojen sensorimotorinen tiedonvälitys on neurologinen tapahtumasarja, jossa 
epäolennainen sensorinen, kognitiivinen tai motorinen ärsyke suodatetaan ja 
vaiennetaan, jotta keskittyminen voidaan kohdistaa merkityksellisiin 
ärsykkeisiin. Sensorimotorinen tiedonvälitys on häiriintynyt esimerkiksi 
Touretten syndroomassa. Tässä väitöskirjassa tutkimme sensorimotorista 
tiedonvälitystä histamiinin, H1-reseptorin sekä H3-reseptorin suhteen 
poistogeenisillä hiirillä. Havaitsimme, että sensorimotorinen tiedonvälitys oli 
häiriintynyt ainoastaan H3-reseptorin suhteen poistogeenisillä hiirillä. Myös 
tämä käyttäytymistason tutkimus siis vahvisti, että ei niinkään histamiini vaan 
ainoastaan sen H3-reseptori on tärkeässä asemassa säätelemässä erilaisia 
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käyttäytymistason toimintoja. Aivojen dopaminerginen järjestelmä säätelee 
näistä kumpaakin, sekä riippuvuuskäyttäytymistä että sensorimotorista 
tiedonvälitystä.  
 
Yllämainittujen käyttäytymiskokeiden perusteella oletimme, että H3-reseptori 
on vuorovaikutuksessa aivojen dopaminergisen järjestelmän kanssa, jota 
seuraavaksi tutkimme solutasolla käyttäen radioaktiivista in situ -hybridisaatiota 
sekä kvantitatiivista geelielektroforeesi -menetelmää. Tutkimustuloksemme 
osoittivat, että H3-reseptorin suhteen poistogeenillä hiirillä ilmentyy vähemmän 
dopamiinin D1-reseptorin lähetti-RNA:ta (engl. messenger RNA, mRNA) 
striatumin alueella. Havaitsimme, että sekä D1-reseptorin että D2-reseptorin 
farmakologinen aktivaatio aiheutti solunsisäisen ERK1/2 –proteiinikinaasin 
aktivaatiota ainoastaan kontrollihiirillä, mutta ei H3-reseptorin suhteen 
poistogeenisillä hiirillä.  
 
Tämä väitöskirjatyö osoittaa että H3-reseptori säätelee niin 
alkoholikäyttäytymistä sekä sensorimotorista tiedonvälittymistä. Näiden 
ilmiöiden mekanismiin liittynee H3-reseptorin ja dopamiinireseptoreiden 
vuorovaikutus aivojen striatumin alueella. Nämä tulokset syventävät 
tietämystämme alkoholikäyttäytymisestä sekä aivojen dopaminergisen 
järjestelmän toiminnasta. Lisäksi prekliiniset tutkimustuloksemme osoittavat, 
että H3-reseptorin farmakologinen salpaus saattaisi olla uusi menetelmä 
alkoholiriippuvuuden hoidossa.   
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ABBREVIATIONS 
 
α-FMH   α-fluoromethylhistidine 
AADC   aromatic l-amino acid decarboxylase 
AA    Alko Alcohol 
AC   adenylyl cyclase 
ADHD   attention-deficit hyperactivity 
AcbC   nucleus accumbens core 
AcbSh   nucleus accumbens shell 
AKT   protein kinase B 
Alcohol-CPP  alcohol-induced conditioned place preference  
Amphetamine-CPP  amphetamine-induced conditioned place preference 
ANA   Alko Non-Alcohol 
ANOVA   analysis of variance 
cAMP   cyclic adenosine monophosphate 
COMT   catechol O-methyltransferase 
CPA   conditioned place aversion 
CPu   caudate putamen 
CPP   conditioned place preference 
CREB   cAMP response element-binding protein 
CSF   cerebrospinal fluid 
CYP450   cytochrome P 450 
DAO   diamine oxidase 
DARPP-32 dopamine- and cAMP-regulated phosphoprotein (32kDa) 
DAT   dopamine transporter 
DID   drinking in the dark 
EDS   extensive daytime sleepiness 
EMA   European medicines agency 
ERK 1/2   extracellular signal-regulated kinase 1/2 
GAD   glutamic acid decarboxylase 
GABA   gamma-aminobutyric acid 
GPCR   G protein-coupled receptor 
GSK3   glycogen synthase kinase 3 
HDC   histidine decarboxylase 
HNMT   histamine N-methyltransferase 
H1R   histamine receptor 1 
H2R   histamine receptor 2 
H3R   histamine receptor 3 
H4R   histamine receptor 4 
KO   knockout 
L-DOPA   L-dihydroxyphenylalanine 
MAO   monoamine oxidase 
MAPK   mitogen-activated protein kinase 
MSN   medium-sized spiny neuron 
NMDA   N-methyl-D-aspartic acid 
OCD   obsessive-compulsive disorder 
PI3K   phosphatidylinositol 3-kinase 
PFC   prefrontal cortex 
PKA   protein kinase A 
PKB   protein kinase B (also termed AKT) 
PLA2   phospholipase A2 
PP1   protein phosphatase 1 
PPI   prepulse inhibition  
RM ANOVA  repeated measures analysis of variance 
SD   standard deviation 
SDS-PAGE  sodium dodecyl sulfate polyacrylamide gel electrophoresis  
SEM   standard error of the mean 
SSC   saline-sodium citrate 
STEP61   striatal-enriched protein tyrosine phosphatase 61  
TH    tyrosine hydroxylase 
TMN   tuberomamillary nucleus 
VMAT   vesicular monoamine transporter 
VTA   ventral tegmental area 
WT   wild type  
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GLOSSARY OF TERMS 
 
 
Addiction 
Addiction is a chronic, relapsing disorder in which compulsive drug-seeking 
and drug-taking behaviors persist despite adverse legal, health, economic, and 
societal consequences. Animal models represent some (e.g. drug dependence) 
but not all aspects of addiction. In this thesis, however, the term addiction is 
used in reference of both human and animal studies. 
 
Constitutive activity 
Several lines of evidence indicate that G protein-coupled receptors (GPCRs), 
including H3R, display significant signal transduction stimulation in the 
absence of activating ligand. This tonic and robust level of stimulation is termed 
constitutive activity. 
 
Inverse agonist 
An inverse agonist is a pharmacological ligand that binds to the same receptor 
as an agonist but induces a pharmacological response opposite to that of an 
agonist, i.e. the receptor turns to its inactive state. Inverse agonism occurs only 
in the constitutively active receptors and decreases their activity below the basal 
level. 
 
Medium-sized spiny neurons (MSNs) 
MSNs also known as spiny projection neurons are a special type of neurons 
representing the vast majority of the neurons within the striatum of the basal 
ganglia. MSNs are GABAergic and thus inhibit the neurons they project to. 
There are at least two types of MSNs in the striatum, one containing D1Rs and 
projecting to substantia nigra (the direct pathway) and the other containing 
D2Rs and projecting mainly to globus pallidus (the indirect pathway). 
 
Neutral antagonist 
A neutral antagonist is a receptor ligand that binds to its receptor without 
affecting its state, i.e. it inhibits or suppresses agonist-mediated or inverse 
agonist-mediated responses. In this thesis, the term antagonist is used for both 
inverse agonists and neutral antagonist as it is not necessarily known whether 
the given ligand acts as an inverse agonist or neutral antagonist. 
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1. INTRODUCTION 
 
The modulatory neurotransmitter histamine is a biogenic amine that is 
synthesized from L-histidine by histidine decarboxylase (HDC) enzyme (Haas 
and Panula 2003; Panula and Nuutinen 2013). Histaminergic neurons are 
located in the posterior hypothalamus in the tuberomamillary nucleus from 
where they send projections to most parts of the brain including striatum, 
cortex, thalamus, cerebellum and spinal cord. The effects of histamine are 
mediated in the brain via three G protein-coupled receptors H1R, H2R and 
H3R. H1R and H2R are postsynaptic receptors whereas H3R is present at both 
presynaptic and postsynaptic sites (Pillot, et al 2002; Haas and Panula 2003). At 
presynaptic locations H3 autoreceptors regulate the release of histamine. H3R is 
also expressed on other neuron terminals regulating the release of e.g. glutamate 
and acetylcholine. In addition, H3R is also localized at the postsynaptic site of 
the MSNs and in these neurons it has been demonstrated that H3R forms 
functional heterodimers with both D1R and D2R in vitro (Ferrada, et al 2008; 
Ferrada, et al 2009). 
 
Histamine in the brain regulates several physiological functions and  histamine 
has been shown to be involved in the pathophysiology of several brain disorders 
including Parkinson’s disease (Rinne, et al 2002), Alzheimer’s disease 
(Mazurkiewicz-Kwilecki and Nsonwah 1989; Airaksinen, et al 1991), 
schizophrenia (Prell, et al 1995) and narcolepsy (Nishino, et al 2001; 
Kanbayashi, et al 2009). Furthermore, altered H3R binding has been associated 
with schizophrenia (Jin, et al 2009). After having been a promising 
pharmacological target in the treatment of various brain disorders for well over 
a decade, H3R antagonist pitolisant (BF2.649, tiprolisant) is finally entering the 
clinical use in the treatment of narcolepsy (EMA 2014). 
 
Studies conducted in rodents have also shown that brain histamine and H3R are 
involved in reward circuit and addiction (Brabant, et al 2010). Interestingly, the 
data from alcoholic humans suggest that the brain histaminergic system is 
altered due to high alcohol (ethanol) consumption (Alakarppa, et al 2002; 
Alakarppa, et al 2003) and the association between H3R and alcohol 
consumption was first found using the alcohol-preferring AA rat line (Lintunen, 
et al 2001). Furthermore, preliminary experiments conducted in HDC KO mice 
also indicated that histamine is involved in the mediation of alcohol-related 
behaviors (Nuutinen, et al 2010). However, these studies left several questions 
unanswered, which were addressed in this thesis. 
 
Recently, an association between hdc gene mutation and Tourette syndrome 
was found in a family with eight children in two generations all carrying the 
mutation, indicating a dysfunction of histaminergic system in Tourette 
syndrome (Ercan-Sencicek, et al 2010). The linkage between the symptoms of 
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Tourette syndrome and the brain histaminergic system has been further 
supported by studies using HDC knockout mice (Castellan Baldan, et al 2014). 
 
Taken together, histamine and H3R have a prominent role in the modulation of 
various brain dysfunctions. However, histamine and H3R seem to rather 
modulate these phenomena and is not directly associated with the etiology of 
the disorders. There is increasing evidence indicating an interaction between the 
dopaminergic and histaminergic systems (Moreno, et al 2011; Moreno, et al 
2014) possibly explaining histamine’s involvement in several brain 
dysfunctions. Revealing how these aminergic systems interact on both 
behavioral and mechanistical level is of great importance in order to better 
understand their functions in both health and disease. In this thesis, the goal was 
to clarify whether histamine and H3R are involved in the regulation alcohol-
related behaviors and symptoms related to e.g. Tourette syndrome and 
schizophrenia in mice. In addition, the aim was to study by which mechanism 
histamine and H3R regulate these behaviors.   
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2. REVIEW OF THE LITERATURE 
 
 
2.1 The brain histaminergic system 
 
The first observation of histamine in the brain was made in the 1940’s 
(Kwiatkowski 1941; Kwiatkowski 1943) but its role as a mammalian 
neurotransmitter was suggested only several decades later (Schwartz, et al 
1976). The histaminergic system was generally acknowledged as a distinct 
anatomically defined neurotransmitter system only in 1984 when it was 
immunohistochemically demonstrated that histaminergic neurons are located in 
the posterior hypothalamus from where they project widely throughout the brain 
(Watanabe, et al 1983; Panula, et al 1984; Watanabe, et al 1984). The sole 
source of histaminergic cell bodies was later found to be identical with the 
previously named tuberomamillary nucleus (TMN). The number of 
histaminergic neurons in the human brain is about 64 000 (Panula, et al 1990) 
whereas in rat 4000 histamine-containing neurons have been observed (Ericson, 
et al 1987). 
 
The histamine neurons are relatively large cells (~25-30 µM in diameter) 
(Panula, et al 1984; Watanabe, et al 1984). Subpopulations of TMN neurons 
also express e.g. substance P, galanin, GABA and its synthetizing enzyme 
glutamic acid decarboxylase (GAD) in addition to histamine (Staines, et al 
1986; Ericson, et al 1991; Airaksinen, et al 1992). However, it is not currently 
known whether these are effectively released from the TMN neurons. 
 
 
2.1.1 Histaminergic projections 
 
The TMN neurons send out projections almost entirely throughout the brain and 
some parts of the spinal cord (Panula, et al 1984; Watanabe, et al 1984)     
(Figure 1). There are two ascending and one descending histaminergic 
pathways innervating the brain (Panula, et al 1989). The ventral ascending 
pathway innervates the ventral part of the brain including the hypothalamus and 
septum, while the dorsal ascending pathway projects to the thalamus, 
hippocampus, amygdala and rostral forebrain structures. The descending 
pathway projects to the cerebellum, brainstem and spinal cord. 
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Figure 1. The histaminergic projections in the human brain. The histaminergic 
neurons originate from the tuberomamillary nucleus located on the posterior 
hypothalamus from where they send projections throughout the brain.  
 
 
The rat TMN has been subdivided into five subdivisions (Inagaki, et al 1990) 
but there is little evidence that these five subnuclei are functionally different 
and they could thus be considered as one functional group (Wada, et al 1991). 
A single neuron from a different TMN subgroup may send divergent 
projections to different parts of the brain and may even project to both 
ascending and descending pathways (Kohler, et al 1985). However, recent 
evidence demonstrates that the histaminergic neurons are functionally 
heterogeneous and organized into distinct circuits (Giannoni, et al 2009) but 
this might more reflect the diversity of the H3R located on the histaminergic 
neurons and not the histaminergic neurons as such. The functional complexity 
of the H3R will be reviewed later in this thesis. 
 
 
2.1.2 Basal ganglia and the striatum 
 
The basal ganglia are a group of subcortical nuclei which comprise the striatum, 
globus pallidus, substantia nigra and subthalamic nuclei. The principal input 
structure of the basal ganglia is the striatum, which can be divided into dorsal 
and ventral striatum (Figure 2). The dorsal part of the striatum is called caudate 
putamen and is implicated especially in the control of motor functions (Girault 
2012). The ventral part of the striatum comprises of nucleus accumbens and 
olfactory tubercle that contains granular cells called the islands of Calleja. 
Ventral striatum is crucial in motivated and goal directed behaviors due to its 
importance in the integration of information from the motor and limbic systems 
(Morgane, et al 2005). The dopaminergic projections from the substantia nigra 
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provide a strong innervation to caudate putamen, whereas the ventral tegmental 
area (VTA) mainly innervates the nucleus accumbens. However, although the 
division of dorsal and ventral striatum in respect to their anatomical and 
functional properties has greatly enhanced the understanding of striatal 
function, it should be kept in mind that this segregation is a simplification and 
many of their functions are overlapping (Voorn, et al 2004). Nevertheless, some 
important functional differences arise from the diversity of the brain structures 
to which these two striatal parts are connected (Girault 2012).  
 
In rodents, about 95 % of the striatal neurons are termed the medium-sized 
spiny neurons (MSNs).  The remaining 5 % of the striatal neurons are mainly 
either GABAergic or cholinergic interneurons (Kawaguchi 1997). There are 
two distinct MSN projection pathways. The direct striatonigral pathway 
comprises MSNs that co-express D1Rs, substance P and dynorphin whereas the 
indirect striatopallidal pathway contains D2Rs and enkephalin (Girault 2012). 
The direct pathway is excited by dopamine and the indirect pathway is inhibited 
by dopamine. 
 
 
 
 
Figure 2. Dorsal and ventral subdivisions of the striatum, their functional 
differences and dopaminergic innervation.  
 
 
2.1.3 Histamine and the striatum 
 
The histaminergic innervation in the basal ganglia is high (Panula, et al 1984; 
Watanabe, et al 1984). HDC mRNA is expressed exclusively in the posterior 
hypothalamus whereas histamine receptors are widespread in the brain, 
indicating that there is functional histaminergic innervation throughout the 
brain, including basal ganglia (Haas, et al 2008; Panula and Nuutinen 2013). 
The amount of HDC protein is high in the hypothalamus and, of importance; it 
is also especially high in the striatum (Krusong, et al 2011). Compared to the 
striatum, HDC protein is 10-fold lower in the cortex, hippocampus and 
cerebellum. However, the histamine content itself is not comparably high in the 
striatum (Oishi, et al 1983; Oishi, et al 1984; Sugimoto, et al 1995), suggesting 
unique characteristics of the histamine metabolism and neurotransmission in the 
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basal ganglia. In support of this, HDC activity has been shown to be greater in 
the striatum compared to hippocampus and cortex (Bischoff and Korf 1978) and 
histamine turnover increased in the striatum compared to other brain regions, 
apart from the hypothalamus (Oishi, et al 1984). Nevertheless, the effect and 
function of histamine in the striatum has not been fully elucidated. Interestingly 
however, HDC deficiency has been linked to TS (Ercan-Sencicek, et al 2010) 
which is a disorder characterized by striatal abnormalities (Peterson, et al 2003; 
Bloch, et al 2005). 
 
 
2.1.4 Histamine synthesis, packaging, release and 
degradation 
 
The amount of histamine penetrating the brain from the blood is negligible 
(Nuutinen and Panula 2010). Histamine in the brain is produced by both mast 
cells (Martres, et al 1975) and neurons (Garbarg, et al 1974). Histamine 
synthesis and metabolism in the brain is illustrated in Figure 3. Histamine 
precursor L-histidine is the rate-limiting factor for histamine synthesis and it is 
brought to neurons by L-amino-acid transporter (LAT). Histamine synthetizing 
enzyme HDC derives L-histidine into histamine (Garbarg, et al 1974). The 
activity of HDC is highest in the TMN but it is also active in histaminergic 
terminals (Watanabe, et al 1983). Histamine is then packed into intracellular 
vesicles by vesicular monoamine transporter (VMAT) (Merickel and Edwards 
1995). Action potential entering the histaminergic nerve terminal induces 
histamine to be released in calcium (Ca
2+
) –dependent manner into the synaptic 
cleft. After its release, histamine is bound to its target receptors and the 
unbound fraction is inactivated by histamine-N-methyltransferase (HNMT) 
induced methylation into tele-methylhistamine (t-mHA) (Brown, et al 1959; 
Reilly and Schayer 1970). Monoamine oxidase B (MAO-B) then converts tele-
methylhistamine into tele-methyl-imidazolaceticacid (t-mIAA) by oxidative 
deamination (Hough and Domino 1979; Hough and Domino 1979). The main 
histamine metabolizing enzyme in the peripheral tissue is diamine oxidase 
(DAO) which is not active in the brain under normal conditions (Prell, et al 
1997). 
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Figure 3. Histamine synthesis and metabolism in the brain. Abbreviations: 
HDC, histidine decarboxylase; HNMT, histamine-N-methyltransferase; LAT, 
L-amino-acid transporter; MAO-B, monoamine oxidase B; t-mHA, tele-
methylhistamine; t-mIAA, tele-methyl-imidazolaceticacid; VMAT, vesicular 
monoamine transporter.  
 
 
2.1.5 Histamine receptors: H1R, H2R and H4R 
 
In this chapter three of the histamine receptors (H1R, H2R and H4R) are shortly 
reviewed. H3R will be discussed in more detail in the following chapters as it is 
the main focus of this thesis. Three of the histamine receptors (H1R, H2R and 
H3R) are widely expressed in the CNS while H4R is expressed mostly in the 
bone marrow and leukocytes (Oda, et al 2000). Whether H4R is also expressed 
in the brain is under debate, some studies suggesting very low levels of H4R in 
different regions of the brain and more prominent expression in the spinal cord 
(Connelly, et al 2009; Strakhova, et al 2009). Molecular and functional 
properties of the four histamine receptors in the brain are listed in Table 1.   
 
The human H1R coding gene is located on the chromosome 3 (Le Coniat, et al 
1994) and like all histamine receptors, belongs to the 7-transmembrane-
spanning G protein-coupled receptor (GPCR) family. More specifically, H1R 
couples to the Gαq/11 protein which activates phospholipase C (PLC) (Traiffort, 
et al 1994). H1R is widely distributed throughout the CNS with the highest 
expression levels in areas important in arousal, e.g. in the thalamus and cortex 
(Chang, et al 1979; Bouthenet, et al 1988). H1R is also highly expressed in the 
limbic system and the striatum. 
 
H2R gene is located on the human chromosome 5 encoding a Gαs protein 
(Traiffort, et al 1995). Activation of Gs protein leads to stimulation of adenylyl 
cyclase (AC) and enhanced production of cyclic adenosine monophosphate 
(cAMP) (Baudry, et al 1975; Hegstrand, et al 1976). H2R is abundant in the 
16 
 
stomach (Diaz, et al 1994) where it is responsible for the gastric acid secretion 
(Hill 1997). H2R is also widespread in the brain and spinal cord (Traiffort, et al 
1992; Vizuete, et al 1997). In the brain, the highest densities of H2R are in the 
basal ganglia and in the limbic structures including hippocampal formation and 
the amygdala, but it is also expressed in the cortex. In contrast to H1R, H2R is 
expressed in low densities in septal areas and hypothalamic and thalamic nuclei.  
The brain H2R has a role for example in cognition and nociception. 
 
The human H4R gene is on the chromosome 18 (Coge, et al 2001) and it shares 
about 35 % amino acid identity with the H3R  and only about 20 % sequence 
similarity with the H1R and H2R (van Rijn, et al 2008). H4R is negatively 
coupled to pertussis toxin-sensitive Gαi/o proteins which inhibit AC 
downregulating cAMP-dependent activation of protein kinase A (PKA) and 
cAMP-response-element binding protein-induced gene transcription (Leurs, et 
al 2009). H4R is expressed e.g. in the bone marrow and leukocytes and is 
involved e.g. in immune responses and various inflammatory conditions (Oda, 
et al 2000).  
 
 
Table 1.  Characteristics of the histamine receptors in the brain. Abbreviations: 
AC, adenylyl cyclase; CNS, central nervous system; MAPK, mitogen-activated 
protein kinase; PLC; phospholipase C.  
 
  H1R H2R H3R  H4R  
Gene locus 
Chromosome     
3 
Chromosome     
5 
Chromosome 
20 
Chromosome 
18 
CNS 
expression High High High ? 
Cellular 
expression  Postsynaptic Postsynaptic 
Pre- and 
postsynaptic Postsynaptic 
G protein Gαq/11 Gαs Gαi/o Gαi/o 
Main signaling 
pathways 
PLC ↑                  
Ca2+↑ AC ↑ 
AC ↓                     
MAPK ↑                              
AC ↓                          
MAPK ↑     
CNS              
function 
Arousal, 
wakefulness 
Cognition, 
nociception 
Cognition 
wakefulness,  ? 
 
 
 
 
 
 
 
 
 
17 
 
2.2  H3 receptor  
 
2.2.1 Physiological functions 
 
Initially H3R was characterized as an autoreceptor in the histaminergic 
terminals regulating the release and synthesis of histamine (Arrang, et al 1983). 
Thereafter, it has been found to act as a heteroreceptor regulating the release of 
several other neurotransmitters, including noradrenaline (Schlicker, et al 1988; 
Schlicker, et al 1994), acetylcholine (Arrang, et al 1995; Blandina, et al 1996), 
GABA (Garcia, et al 1997; Yamamoto, et al 1997) and glutamate (Molina-
Hernandez, et al 2001). Interestingly, in the caudate putamen and nucleus 
accumbens H3R is mainly expressed at the postsynaptic site on the MSNs of 
both the direct and indirect movement pathways (Pillot, et al 2002). The role of 
the postsynaptic H3Rs has been only quite recently elucidated and is thought to 
directly regulate the function of the dopaminergic receptors (Ferrada, et al 
2008; Ferrada, et al 2009). 
 
 
2.2.2 Localization and distribution in the brain 
 
H3R is widely expressed in the brain with the highest expression in the cerebral 
cortex, the striatum, the olfactory tubercles and the substantia nigra (Pollard, et 
al 1993). The localization of the H3R parallels that of its mRNAs in some areas 
of the brain, but interestingly there are some discrepancies between the presence 
of the protein and it’s mRNA in many brain regions (Pillot, et al 2002). In the 
cerebral cortex for example, H3R mRNA expression is found in all layers and 
displays a distinct laminar pattern (Pillot, et al 2002; Jin and Panula 2005). 
There is a strong mRNA expression of H3R in the intermediate and deep layers, 
indicating the presence of H3R on several types of neurons. The H3R binding is 
also dense in the cortex except in layer V. The very high mRNA expression 
observed in cortical layer V encodes probably for the presynaptic H3Rs 
regulating glutamate release from the corticostriatal neurons. In the 
hippocampus, there is strong mRNA expression but low binding in pyramidal 
layers of the CA1, indicating that H3Rs are more abundant on the efferent 
projections of pyramidal cells. Some studies have found no H3R mRNA in the 
dopaminergic neurons (Anichtchik, et al 2001; Drutel, et al 2001) whereas 
Pillot and colleagues found both H3R binding and H3R mRNA expression in 
the substantia nigra pars compacta and suggesting that H3Rs are located upon 
nigrostriatal afferents (Pillot, et al 2002). Interestingly, however, no H3R 
mRNA was observed in the VTA indicating that not all dopaminergic neurons 
express H3Rs. In contrast, a recent study demonstrated that H3R mRNA is 
expressed in the VTA (González-Sepúlveda, et al 2013). In the amygdala, there 
are both high density of receptor and mRNA expression. High expression of 
H3R mRNA is also observed in the thalamus (Pillot, et al 2002; Jin, et al 2002; 
Jin, et al 2005) whereas the binding is not that abundant. In the hypothalamus, 
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the H3R mRNA expression parallels the density of binding sites with the 
highest being in the TMN. 
 
 
2.2.3 H3R in the basal ganglia and the striatum 
 
For clarity, the localization of the H3R in the basal ganglia is schematically 
illustrated in Figure 4. Of importance, in both rodent and human basal ganglia, 
high densities of both H3R mRNA and binding sites have been observed. The 
highest density of H3R has been observed in both dorsal and ventral striatum 
(Pillot, et al 2002). The striatal H3Rs are mainly located on the GABAergic 
MSNs projecting to the globus pallidus and substantia nigra, hence the striatal 
H3Rs are mainly postsynaptic. In the MSNs H3Rs are colocalized with both 
D1RS and D2Rs (González-Sepúlveda, et al 2013; Moreno, et al 2011; Ryu, et 
al 1994). The H3RS in the D1R-containing striatonigral pathway are functional 
as it has been shown that H3R activation reduces D1R-dependent GABA 
release (Arias-Montano, et al 2001) and inhibits D1R-mediated cAMP 
accumulation (Sanchez-Lemus and Arias-Montano 2004). The proenkephalin 
and D2R-containing striatopallidal MSNs also express H3R mRNA (Pillot, et al 
2003) and but the functional role of the H3Rs in the striatopallidal neurons has 
not been fully elucidated. 
 
Functional studies indicate the presence presynaptic H3Rs upon striatal 
afferents as the H3 autoreceptors modulate histamine release from rat striatal 
slices (Arrang, et al 1985). In addition, there is also some evidence that H3R 
regulates the release of dopamine from the dopaminergic neurons (Molina-
Hernandez, et al 2000; González-Sepúlveda, et al 2013). Moreover, the 
presence of presynaptic H3Rs located on the inputs from the striatal cholinergic 
interneurons has also been observed (Chazot, et al 2001; González-Sepúlveda, 
et al 2013). In addition, H3Rs are also located on the corticostriatal 
glutamatergic terminals, a finding that is also supported indirectly by the H3R-
mediated inhibition of striatal glutamate release (Molina-Hernandez, et al 
2001). 
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Figure 4. H3R in the subcortical structures forming the basal ganglia circuitry. 
Abbreviations: DA, dopamine; D1R, dopamine receptor 1; D2R, dopamine 
receptor 2, HA, histamine; H3R, histamine receptor 3; MSN, medium spiny 
neuron; SN, substantia nigra; TMN, tuberomamillary nucleus; VTA, ventral 
tegmental area. References to original publications are found in the text. 
     
 
2.2.4 Splice variants 
 
The human H3R was cloned in the late 1990’s (Lovenberg, et al 1999) and the 
availability of the human H3R cDNA has not only had a great impact on 
understanding the diversity of the H3R and but also on drug development. The 
human H3R gene is located on chromosome 20q13.33 and it encodes the small, 
70 kDa peptide consisting of 445 amino acids. The sequence similarity of H3R 
with other GPCRs is very low and the similarity with both H1Rs and H2Rs is 
only about 20 % (Leurs, et al. 2005). H3R has several different human and rat 
isoforms that are derived from a single gene by alternative splicing (Lovenberg, 
et al 1999; Drutel, et al 2001; Coge, et al 2001; Rouleau, et al 2004). At least 
20 different human H3R isoforms have been described, but as most of the 
observations of the H3R have been detected by mRNAs, it cannot be 
determined whether they are also functionally active (Leurs, et al 2005). It has 
been shown, however, that different H3R isoforms differ in their localization 
and pharmacological properties such as signal transduction efficiencies (Drutel, 
et al 2001; Hancock, et al 2003). The heterogeneous distribution of the isoforms 
suggests that H3R may display isoform-specific regulation of different brain 
functions. At least six of the human H3Rs; H3R(453), H3R(445), H3R(409), H3R(373), 
H3R(329) have been shown to have functional activity either by ligand-binding or 
signal transduction experiments (Leurs, et al 2005). In the rat, at least four 
isoforms have been described as functionally active; H3R(445), H3R(413), 
20 
 
H3R(410), H3R(397) (Esbenshade, et al 2008) and the form H3R(413) has been 
suggested to function as the presynaptic H3 autoreceptor (Gbahou, et al 2012). 
Better understanding of the specific characteristics of the different H3R 
isoforms in terms of functional properties and localization would help to 
elucidate the functional complexity of the H3R. 
 
 
2.2.5 Constitutive activity 
 
The high constitutive activity of the H3R was first shown in the rat recombinant 
H3R by Morisset and colleagues leading to the suggestion that H3R inverse 
agonist might have therapeutic applications (Morisset, et al 2000). Shortly after, 
it was shown that also the human H3R display high level of activity in the 
absence of an agonist (Wieland, et al 2001; Rouleau, et al 2002). The 
recognition of the in vivo constitutive activity of the H3R has allowed more 
detailed characterization of the pharmacological ligands and has led to the 
understanding that many of the ligands originally classified as H3R antagonists 
are in fact inverse agonists (Arrang, et al 2007). The constitutive activity of the 
H3R is not only of importance in the regulation of the activity of 
pharmacological ligands but it is also likely to have a major modulatory role in 
the brain. 
 
 
2.2.6 Signaling 
 
Similarly to the H4R, the effects of H3R are mediated via Gαi/o  protein (Clark 
and Hill 1996; Lovenberg, et al 2000) that is negatively coupled to AC. AC 
stimulates the production of cAMP, which in turn activates PKA and cAMP-
responsive-element binding protein (CREB) modulating gene transcription. 
Thus, H3R activation reduces the level of cAMP and its downstream targets 
such as CREB. 
 
H3R may also engage Gαq/11 through extensive cross-talk with other GPCRs. 
Activation of Gαq/11 leads to activation of PLC. PLC, in turn, induces the 
activation of protein kinase C (PKC). Subsequently, in addition to inhibition of 
the cAMP pathway, H3R may also activate other effector pathways including 
mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase 
(PI3K) pathways (Drutel, et al 2001; Giovannini, et al 2003). Activation of 
MAPK results in the phosphorylation of ERK1/2 whereas activation of PI3K 
leads to activation of protein kinase B (PKB, also termed AKT) (PKB, also 
termed AKT) (Bongers, et al 2007; Mariottini, et al 2009). AKT 
phosphorylation subsequently inhibits the action of glycogen synthase kinase 3β 
(GSK3β), which is the major tau kinase in the brain involved for example in the 
pathophysiology of Alzheimer’s disease (Sun, et al 2002). 
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H3R-mediated activation may also lead to activation of phospholipase A2 
(PLA2) inducing the release of arachidonic acid (Rouleau, et al 2002), inhibition 
of sodium/hydrogen (Na
+
/H
+
) exchanger and reduction of the intracellular Ca
2+
 
levels (Silver, et al 2002). 
 
 
2.2.7 H3R antagonists 
 
The first synthesized H3R selective and potent H3R antagonist was the 
imidazole-based thioperamide (Arrang, et al 1988). Thioperamide has been 
extensively used in the preclinical research. There are several other imidazole-
based H3R antagonists used in in vitro or in vivo animal studies, but their major 
drawback is the imidazole group in the compound leading to interference with 
the metabolizing cytochrome P450 (CYP450) enzymes in the liver and possible 
pharmacokinetic interactions with other drugs (Yang, et al 2002; Berlin, et al 
2006). Another drawback of an imidazole-containing compound is a poor brain 
penetration (Schwartz 2011). The discovery that the imidazole residue can be 
replaced by nitrogen-containing heterocycles has led to the development of 
several non-imidazole-based H3R antagonists by different pharmacological 
companies for various indications, focusing on different CNS implications. The 
first H3R antagonist that was introduced to the clinical trials was the potent, 
brain-penetrant, highly selective and orally bioavailable pitolisant (Ligneau, et 
al 2007; Schwartz 2011). 
 
 
2.3  The brain histamine and H3R antagonism in health and 
disease 
 
Histamine in the brain regulates several physiological functions and has been 
shown to be involved in the pathophysiology of several brain disorders 
including Parkinson’s disease (Rinne, et al 2002), Alzheimer’s disease 
(Mazurkiewicz-Kwilecki and Nsonwah 1989; Airaksinen, et al 1991), 
schizophrenia (Prell, et al 1995) and narcolepsy (Nishino, et al 2001; 
Kanbayashi, et al 2009). Histamine release is also a sensitive indicator of stress 
(Verdiere, et al 1977; Westerink, et al 2002). In addition, increased H3R 
radioligand binding has been observed in the prefrontal cortex (PFC) of 
schizophrenic and bipolar subjects with psychotic symptoms (Jin, et al 2009). 
 
The research on the role of the brain histaminergic system in brain disorders has 
largely focused on H3R-mediated modulation of the dysfunctions and the first 
histaminergic drug implicated for CNS disorder is likely to be H3R antagonist 
pitolisant in the treatment of narcolepsy (Dauvilliers, et al 2013). The literature 
about the histaminergic system and especially H3R in health and disease are 
reviewed in the next chapters. 
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2.3.1 Sleep, arousal and wakefulness 
 
Indirect pharmacological evidence of brain histamine as a regulator of sleep 
arose from the sedative adverse effect of the classic antihistamines acting as 
H1R antagonists used in the treatment of allergies (Monnier, et al 1967). The 
critical role of the histaminergic neurons in the maintenance of wakefulness was 
suggested a decade later (Schwartz 1977).  Histamine is released in a circadian 
rhythm from the TMN which parallels the alterations in the firing rate of the 
histaminergic neurons throughout the sleep-wake cycle (Mochizuki, et al 1992). 
Neuronal histaminergic neurons act as pacemaker cells that are intrinsically able 
to generate rhythmic bursting activity and display spontaneous firing with low 
frequency (1-4 Hz) (Haas and Panula 2003). The activity of the histaminergic 
neurons is high during waking and low or absent during sleep (Saper, et al 
2005) and the activity of histaminergic TMN neurons is important in the 
maintenance of the high level of vigilance necessary for cognitive processes 
(Takahashi, et al 2006). Mice lacking endogenous histamine (HDC KO) are less 
vigilant and fall asleep faster than control mice in a novel environment 
(Parmentier, et al 2002). In human cerebrospinal fluid (CSF), histamine 
concentration is highest during the day (Kiviranta, et al 1994).  In addition to 
the circadian rhythmicity, histamine is released rapidly, in an ultradian rhythm 
correlating with the delta and theta waves in the electroencephalographic 
recordings (Philippu and Prast 1991). 
 
Narcolepsy is a disabling sleep disorder characterized by disturbed nocturnal 
sleep and excessive daytime sleepiness (EDS) (Dauvilliers, et al 2007). 
Narcolepsy is often accompanied with cataplexy; the sudden loss of muscle 
tone. In humans, narcolepsy is caused by deficient neurotransmission of orexin 
(hypocretin) (Peyron, et al 2000). Orexin is as excitatory peptide originating 
from the lateral hypothalamus and it has widespread projections in the brain. Of 
importance, the orexinergic system mainly projects to aminergic neurons 
including the histaminergic neurons. Interestingly, there is also evidence that 
the activation of histaminergic neurotransmission is required for the waking 
action of orexin (Huang, et al 2001). Lower levels of CSF histamine have been 
observed in subjects suffering from idiopathic insomnia or narcolepsy 
(Kanbayashi, et al 2009; Nishino, et al 2009). The immense preclinical 
evaluation of the efficacy of H3R antagonists in animal models of narcolepsy 
has resulted in clinical drug development (Tiligada, et al 2011). Several H3R 
antagonists have been studied in clinical trials in narcoleptic patients suffering 
from EDS. The most advanced compound in the H3R antagonist drug 
development is the pitolisant that has a proven efficacy in a phase III study 
(Lin, et al 2008; Dauvilliers, et al 2013). Bioprojet Pharma has recently 
submitted an application to the European Medicines Agency (EMA) for 
pitolisant (Wakix®) as a new human medicine (EMA 2014). 
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2.3.2 Cognitive deficits 
 
In animal models, H3R antagonists improve cognitive performance probably by 
increasing the release of histamine and enhancing histamine-mediated attention 
and vigilance (Cowart, et al 2005; Medhurst, et al 2007; Chauveau, et al 2014). 
As H3R also regulates the release of other neurotransmitters important in 
cognitive processes, e.g. acetylcholine and glutamate, it is plausible that H3R 
antagonism improves cognitive performance via increasing the release of these 
neurotransmitters.  
 
Alzheimer’s disease is the most common form of dementia associated with 
cognitive dysfunctions (Mattson 2004). Post mortem studies have revealed that 
there are deficits in the brain histaminergic system in Alzheimer’s disease 
patients (Mazurkiewicz-Kwilecki and Nsonwah 1989; Panula, et al 1998). 
Histamine levels are lower in individuals with Alzheimer’s disease compared to 
healthy controls e.g. in cortical areas, hippocampus and hypothalamus. 
Furthermore, there are neurofibrillary tangles in the TMN neurons of 
Alzheimer’s disease patients (Airaksinen, et al 1991). Several H3R antagonists 
have been or are currently being investigated in clinical phase II trials in the 
treatment of cognitive dysfunctions in Alzheimer’s disease, attention-
deficit/hyperactivity disorder (ADHD) and schizophrenia (Tiligada, et al 2011). 
MK-3134 alone improved the cognitive impairment associated with 
scopolamine in healthy humans (Cho, et al 2011). The compound also had an 
additive positive effect on the scopolamine-induced cognition impairment when 
administered together with a cholinesterase inhibitor donepezil. However, 
another H3R antagonist MK-0249 over four weeks was not effective in 
improving cognitive function in Alzheimer’s disease patients (Egan, et al 2012). 
GSK239512 displayed positive effects on attention and memory in Alzheimer’s 
disease patients, but unsatisfactory level of tolerability (Nathan, et al 2013). 
However, by altering the dosing regimen, the tolerability might be improved. 
Another H3R antagonist ABT-288 has been evaluated for safety and tolerability 
in both young and elderly subjects (Othman, et al 2013) but the phase II results 
in Alzheimer’s disease patients have not yet been published. 
 
In addition to Alzheimer’s disease, there are cognitive deficits in other disorders 
including ADHD. ADHD is a neuropsychiatric disorder that is characterized by 
inappropriate and persistent symptoms of inattention, impulsivity and/or 
hyperactivity, and motor restlessness. The published clinical evidence has not 
supported the effectiveness of H3R antagonists in the treatment of ADHD. MK-
0249 was not effective in treatment of adult ADHD although it has been shown 
to have alertness-promoting affect in humans (Herring, et al 2012). Neither did 
another, highly selective, wakefulness-promoting H3R antagonist bavisant 
display significant clinical effects in the treatment of adults with ADHD 
(Weisler, et al 2012). However, a preliminary finding with pitolisant suggests 
that it might result in progressive improvement in adults with ADHD (Schwartz 
2011). 
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Schizophrenia is a chronic and disabling mental brain disorder characterized 
by a wide range of psychological symptoms including delusions and altered 
social behavior. In addition, higher cognitive functions are often disturbed in 
schizophrenia. It has been demonstrated that the histaminergic system is altered 
in patients with schizophrenia. The level of tele-methylhistamine in the CSF, 
representing the released and metabolized histamine, has been reported to be 
increased in individuals with schizophrenia (Prell, et al 1995). In addition, H3R 
binding was increased in the dorsolateral PFC in patients with schizophrenia 
(Jin, et al 2009). Interestingly, ABT-288 is tolerated at significantly higher 
doses in subjects with schizophrenia than in healthy volunteers (Othman, et al 
2014). However, ABT-288 has been associated with an increased incidence of 
psychosis- and sleep-related adverse events in a phase II trial (Haig, et al 2014). 
Furthermore, neither ABT-288 nor MK-0249 resulted in cognitive improvement 
in adults with schizophrenia (Egan, et al 2013; Haig, et al 2014). 
 
Taken together, H3R antagonists may have cognition improving properties in 
disorders including Alzheimer’s disease, ADHD and schizophrenia. 
Nevertheless, to date, the clinical data available indicates that the therapeutic 
potential of H3R antagonists in cognitive deficits is rather weak. However, 
although the effects of H3R antagonists alone might be inadequate as cognition 
enhancers, they may potentially have additive effects when used in combination 
with other drugs. 
 
 
2.3.3 Motor dysfunctions 
 
Tourette syndrome is a neurological disorder characterized by repetitive, 
stereotyped, involuntary movements and vocalizations termed motor and vocal 
tics, respectively. Individuals with Tourette syndrome also display deficits in 
sensorimotor gating (Swerdlow 2013). Genetic evidence has indicated that a 
dysfunction of the histaminergic system may be important in the 
pathophysiology of Tourette syndrome. The occurrence of Tourette syndrome 
in two generations of a family with eight children was associated with a highly 
penetrant, rare but functional mutation in a gene coding for HDC (hdc) (Ercan-
Sencicek, et al 2010). Later studies conducted in patients with Tourette 
syndrome and HDC KO mice have thereafter supported the role of the brain 
histaminergic system in Tourette syndrome (Fernandez, et al 2012; 
Karagiannidis, et al 2013; Castellan Baldan, et al 2014). These studies 
suggested that tics could possibly be treated by increasing histaminergic 
activity. A case study reported that EDS was decreased by pitolisant in a patient 
suffering from both Tourette syndrome and narcolepsy, but there was no clear 
decrease in tics (Hartmann, et al 2012). 
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Parkinson’s disease is a progressive disorder characterized by motor 
disturbances including bradykinesia, hypokinesia and impaired bilateral 
coordination as a result from the degeneration of the dopaminergic neurons in 
the substantia nigra leading to a depletion of dopamine in the striatum. 
Parkinson’s disease has also been associated with increased histamine levels in 
the basal ganglia (Rinne, et al 2002). Furthermore, the morphology of the 
histaminergic fibers is altered and the density of histaminergic fibers in the 
substantia nigra is increased in Parkinson’s disease (Anichtchik, et al 2000). 
The increased histamine levels and histaminergic innervation might reflect 
compensatory events due to dopamine deficiency (Panula and Nuutinen 2013). 
Individuals with Parkinson’s disease often suffer from insomnia which may be 
an outcome of the increased histaminergic tone. Interestingly, the TMN neurons 
are excited by the commonly used anti-parkinsonian treatment L-DOPA and are 
able to take up and decarboxylate L-DOPA to dopamine (Yanovsky, et al 
2011). Thus, the histaminergic neurons can co-release dopamine and histamine 
from their widely distributed projections. There is also an increase of H3R 
binding density in the substantia nigra of individuals with Parkinson’s disease 
(Anichtchik, et al 2001) while there is no difference in H3R binding in other 
parts of basal ganglia, including the striatum and globus pallidus between 
healthy controls and patients with Parkinson’s disease (Goodchild, et al 1999). 
In rodent models of Parkinson’s disease, it has been shown that H3R ligands 
have effects on motor coordination and apomorphine-induced stereotyped 
behaviors (Anichtchik, et al 2000; Gomez-Ramirez, et al 2006; Nowak, et al 
2008; Nowak, et al 2009). However, there is no clinical data supporting the use 
of H3R antagonists for motor disturbances in Parkinson’s disease. Nevertheless, 
pitolisant has been shown to reduce sleepiness in patients with Parkinson’s 
disease, while the motor symptoms remained unaffected (Schwartz 2011). 
 
Huntington’s disease is an inherited neurodegenerative disorder affecting 
muscle coordination and cognitive functions associated with the loss of striatal 
and cortical projection neurons (Chen, et al 2013). The imbalance in brain 
dopaminergic functions contribute to abnormal movements and cognitive 
deficits in Huntington’s disease. In Huntington’s disease patients, TMN volume 
and neuronal number is unaltered, whereas HDC mRNA is increased and 
striatal H3R mRNA decreased (van Wamelen, et al 2011). In addition, H3R 
binding is lower in Huntington’s disease patients compared to healthy controls 
in the caudate putamen and globus pallidus (Goodchild, et al 1999). However, 
there are no published studies on the possible effects of H3R antagonists in the 
treatment of Huntington’s disease. 
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2.3.4 Drug addiction 
 
It was found already in the 1970’s that histamine modulates reinforcement in 
experimental animals (Cohn, et al 1973). These studies formed the basis for the 
hypothesis that histamine plays an inhibitory role in reward and opposes the 
effect of dopamine in reward and reinforcement.  Histamine injected to the 
lateral hypothalamus of rats inhibited electrical self-stimulation at the injection 
site without affecting self-stimulation in the contralateral lateral hypothalamus. 
This effect was blocked by prior treatment with H1R antagonist pyrilamine. 
Self-stimulation is also increased in TMN lesioned rats, suggesting that 
destruction of the histaminergic neurons increases addictive behaviors (Wagner, 
et al 1993; Wagner, et al 1993).  
 
In support of the inhibitory role of histamine in reward, it has been 
demonstrated that the histamine precursor, L-histidine, attenuates morphine-
induced place preference, while an HDC inhibitor, α-fluoromethylhistidine (α-
FMH), potentiates morphine reward (Suzuki, et al 1995). HDC KO mice also 
display stronger morphine-induced (Gong, et al 2010) and alcohol-induced CPP 
(Nuutinen, et al 2010) compared to control mice. However, contradictory 
findings to the reward inhibitory role of histamine have also been published. 
Surprisingly, α-FMH infused to the lateral hypothalamus decreased, rather than 
decreased self-stimulation (Zimmermann, et al 1997). Furthermore, in oppose 
to the inhibitory function of histamine in reward, HDC KO mice have been 
shown to be less stimulated by cocaine whereas no differences were observed 
between HDC KO and control mice in cocaine-induced CPP (Brabant, et al 
2007). 
 
Systemically injected acute alcohol has no effect on the histamine concentration 
in the mouse hypothalamus, whereas the level of tele-methylhistamine is 
increased after high doses of alcohol, suggesting that alcohol affects histamine 
turnover in the brain (Itoh, et al 1985; Zimatkin and Anichtchik 1999). In rats, it 
has been shown that alcohol-induced motor impairment and alcohol sensitivity, 
as measured by the tilting plane test, can be increased by lowering the brain 
histamine content with α-FMH (Lintunen, et al 2002). However, no differences 
were observed between HDC KO and WT mice in the accelerating rotarod test, 
another measure for alcohol-induced motor impairment (Nuutinen, et al 2010). 
 
The association between H3R and alcohol consumption was first found using 
alcohol-preferring AA rat line (Lintunen, et al 2001; Lintunen, et al 2002). 
These studies demonstrated that the histamine levels of the AA rats were 
elevated compared to those in alcohol-avoiding ANA rats. H3R antagonists 
thioperamide and clobenpropit also decreased, whereas an H3R agonist R-α-
methylhistamine increased, alcohol consumption. Clobenpropit has also been 
shown to inhibit morphine-induced CPP in a dose dependent manner (Wang, et 
al 2009) and morphine increases the turnover of neuronal histamine (Nishibori, 
et al 1985). 
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The results of the role of histamine and H3R antagonism on the effects of 
psychostimulants deviate from those obtained with alcohol and morphine. 
Acute cocaine has been shown to increase the striatal histamine and HNMT 
activity (Ito, et al 1997). Interestingly however, thioperamide induces place 
preference with a low dose of cocaine, which is inactive per se (Brabant, et al 
2005) and increases cocaine-induced locomotor stimulation (Brabant, et al 
2009). Repeated administration of methamphetamine also increases HDC 
activity in the striatum and cortex and the release of histamine in the cortex (Ito, 
et al 1996; Dai, et al 2004). H3R antagonists clobenpropit and thioperamide 
also potentiate methamphetamine self-administration and methamphetamine-
induced accumbal dopamine release (Munzar, et al 2004). The contradictory 
results for the role of H3R in alcohol and morphine reward in comparison to 
results obtained with psychostimulants might therefore arise from a 
pharmacokinetic interaction (Panula and Nuutinen 2013). This hypothesis is 
supported by a study demonstrating that cocaine concentrations in the plasma 
are elevated by coadministration of thioperamide (Brabant, et al 2009).  
Importantly, both methamphetamine and cocaine are metabolized by liver 
microsomal CYP450 enzymes which are a common pathway of metabolism for 
both psychostimulants and imidazole-based compounds such as clobenpropit 
and thioperamide. As the common liability of an imidazole-containing 
compound is the inhibition of CYP450 enzymes, the interaction may lead to 
higher concentration of the psychostimulants in the blood. 
 
There are only few human studies on the role of histamine in addiction. In 
methamphetamine dependent subjects, H1R antagonist hydroxyzine had no 
effect over placebo in reducing methamphetamine use, retaining patients in 
treatment or reducing methamphetamine craving (Ling, et al 2012). Postmortem 
studies from alcoholic subjects have suggested that the brain histamine turnover 
is altered due to high alcohol consumption, with alcoholics having elevated 
histamine content in the grey matter (Alakarppa, et al 2002). Additionally, 
another study demonstrated increased concentrations of histamine and tele-
methylhistamine and down-regulation of H3R binding in the brains of patients 
with liver cirrhosis (Lozeva, et al 2003). The majority of the cirrhotic patients 
were alcoholics.  Interestingly, the histaminergic system has also been 
associated with alcohol addiction via genetic polymorphism (Oroszi, et al 2005; 
Reuter, et al 2007). A common and functionally significant polymorphism in 
the HNMT gene results in a Thr105Ile substitution of the protein encoded, 
leading to approximately 2-fold higher enzyme activity. These studies on the 
polymorphism of the HNMT have revealed an association between alterations 
in the brain histamine and vulnerability to alcoholism. 
 
Although the human data on the role of histamine, H3R and addiction is very 
limited, the preclinical data obtained in this thesis suggests that H3R antagonists 
might be an interesting novel approach to treat alcohol addiction and this 
hypothesis should be tested in humans. 
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2.4  The brain dopaminergic system 
 
There are five abundant biogenic amines in the human body: dopamine, 
noradrenaline, adrenaline, serotonin and histamine. Of these, noradrenaline, 
adrenaline and dopamine are catecholamines with dopamine being most 
abundant catecholamine neurotransmitter in the brain, constituting about 80 % 
of the catecholamine content in the brain. Dopamine was initially identified as 
the metabolic precursor of noradrenaline but in the 1950s it was recognized as a 
neurotransmitter in the mammalian brain (Carlsson, et al 1957; Carlsson, et al 
1958).  
 
Like other catecholamines, dopamine is derived from L-tyrosine. In the first 
enzymatic reaction tyrosine hydroxylase (TH) catalyses L-3,4-
dihyfroxyphenylalanine  (L-DOPA) from L-tyrosine (Nagatsu, et al 1964). TH 
is the rate-limiting enzyme of this pathway. L-DOPA is then converted to 
dopamine by aromatic L-amino acid decarboxylase (AADC) (Lovenberg, et al 
1962). Following its synthesis, dopamine is packed into synaptic vesicles via 
VMAT2. Once released from the presynaptic nerve terminals, the action of 
dopamine is terminated by reuptake by sodium (Na
2+
)-dependent dopamine 
transporter (DAT) (Nirenberg, et al 1997). The two major enzymes involved in 
dopamine metabolism are monoamine oxidase (MAO) and catechol O-
methyltransferase (COMT) (Napolitano, et al 1995). 
 
Dopaminergic projections originate from the mesencephalic neurons from the 
substantia nigra and VTA and the dopaminergic neurons innervate several 
regions of the brain. The dopaminergic neurons project mainly to striatum, PFC 
and amygdala, of which the two first ones are implicated in the pathophysiology 
of numerous neurological diseases including addiction (Swanson 1982; 
Lammel, et al 2014). More specifically, the cell bodies of the dopamine neurons 
innervating the caudate putamen are located in the substantia nigra (nigrostriatal 
pathway), while the dopaminergic neurons projecting to the nucleus accumbens 
and limbic structures are located more medially in the VTA (mesolimbic 
pathway)  (Girault and Greengard 2004).  
 
Dopaminergic neurons are pacemakers and spontaneously active at low 
frequencies (around 5 Hz) providing a basal dopaminergic tone to their target 
neurons that may be rapidly adjusted by either phasic bursts or transient pauses 
of activity (Tritsch and Sabatini 2012). Dopamine cannot be characterized as 
neither excitatory nor inhibitory neurotransmitter, but functions rather as a 
neuromodulator altering the responses of its target neurons (Girault and 
Greengard 2004). The dopaminergic system is involved in several CNS 
disorders including Parkinson’s disease, Tourette syndrome and addiction.   
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2.4.1 Receptors 
 
Dopamine activates multiple GPCR subtypes that are heterogeneously 
distributed and engage different intracellular cascades (Tritsch and Sabatini 
2012). Dopamine receptors D1R-D5R are distinct but closely related and can be 
divided into two major classes based on their structural, pharmacological and 
signaling characteristics. These families are termed D1-like and D2-like 
receptors. D1R and D5R belong to the D1-like family whereas D2R, D3R and 
D4R belong to the D2-like family. Receptors share a high level of homology 
inside the D1-like and D2-like receptor families at a protein level and 
pharmacological ligands may readily distinguish between the receptor families. 
However, ligand specificity between individual receptor subtypes within a 
receptor family is often lacking (Beaulieu and Gainetdinov 2011). Dopamine 
has higher affinity for the D2-like receptors, and the affinity is especially high 
for the short splice variant D2s –receptor, which is mainly located 
presynaptically (Usiello, et al 2000).       
 
D1R and D2R stimulate and inhibit AC, respectively. However, even though 
D1R and D2R have opposite effects on the molecular level, they often have a 
synergistic function when more complex outputs are considered (Girault and 
Greengard 2004). D1Rs and D2Rs are most prominently expressed in the 
caudate putamen, nucleus accumbens and olfactory tubercle (Vallone, et al 
2000). In the striatum, as already described earlier, the direct striatonigral 
pathway contains D1Rs, whereas the indirect striatopallidal pathway expresses 
D2Rs. Although D1Rs and D2Rs are predominantly expressed in different 
MSN subpopulations, recent studies have demonstrated that they can also 
coexist within the same MSNs expressing both dynorphin and enkephalin 
(Perreault, et al 2010). However, it has been estimated that the number of cells 
containing both D1R and D2R is less than 5 % (Matamales, et al 2009). These 
D1R/D2R coexpressing neurons are likely to contribute to the maintenance of 
the homeostatic balance between the direct and indirect pathways. 
 
 
2.4.2 Signaling 
 
Dopaminergic receptors activate numerous signal transduction pathways; 
nevertheless the best-characterized ones include the dopamine-mediated 
activation or inhibition of the cAMP pathways and the modulation of Ca
2+
- 
signaling.  
 
D1R is positively coupled to AC through Gαs proteins. AC activates cytosolic 
cAMP production which in turn leads to activation of PKA and phosphorylation 
of various intracellular downstream targets (Herve, et al 1995). In contrast, D2R 
is negatively coupled to AC through Gαi/o proteins. The activation of D2R 
therefore leads to inhibition of AC and reduction of cytosolic cAMP production 
(Stoof and Kebabian 1984). D2Rs also modulate the intracellular Ca
2+
 levels by 
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acting on ion channels or by triggering the release of intracellular Ca
2+
 storages 
(Beaulieu, et al 2007).  Interestingly, recent findings demonstrate that neurons 
that contain both D1Rs and D2R are able to form D1R-D2R heteromers that 
couple to the Gαq protein (Rashid, et al 2007). This enables dopamine to have 
various effects on second messengers, depending whether the given neuron 
contains D1Rs, D2Rs or D1R-D2R heteromers.  
 
There are three major signaling cascades involved in the regulation of signal 
transduction in response to dopamine: PKA-DARPP-32, ERK1/2 and AKT-
GSK3 pathways. These cascades are shortly described next and illustrated in 
Figure 5. 
 
Dopamine- and cAMP-regulated phosphoprotein, 32 kDa (DARPP-32) is 
the best-characterized substrate of dopaminergic signal transduction. DARPP-
32 is highly enriched in the striatum in both striatonigral and striatopallidal 
MSNs (Ehrlich, et al 1990; Ouimet, et al 1998). DARPP-32 can be 
phosphorylated in several different amino acid residues, with threonine-34 
(Thr
34
) and threonine-75 (Thr
75
) being the most common targets of 
phosphorylation (Girault 2012). In the striatonigral MSNs, DARPP-32 is 
phosphorylated on Thr-
34
 upon stimulation of D1Rs, whereas in striatopallidal 
MSNs the same response is triggered by D2R antagonism (Bateup, et al 2008). 
Activation of D1R and the following PKA-mediated phosphorylation of 
DARPP-32 at Thr
34 
leads
 
to inhibition of protein phosphatase 1 (PP1) (Walaas, 
et al 1983; Hemmings, et al 1984). PP1 is important in a wide range of 
biological processes, from muscle contraction to memory formation (Choy, et al 
2012). In contrast, D2R activation-mediated inhibition of AC leads to 
dephosphorylation of DARPP-32 at Thr
75 
(Nishi, et al 1997). Importantly, when 
DARPP-32 is phosphorylated at Thr
75
 it becomes an inhibitor of PKA
 
(Bibb, et 
al 1999). Thus, regulation of DARPP-32 phosphorylation at either Thr
34
 or 
Thr
75 
appears
 
to function in a bidirectionally and modulate dopaminergic signal 
transduction in a complementary manner (Bateup, et al 2008). Importantly, this 
complex positive feedback loop potentiates dopaminergic signaling. There is 
increasing evidence of DARPP-32 being the mediator of the effects of different 
drugs of abuse (Nairn, et al 2004; Girault 2012). For example, alcohol, 
amphetamine, opioids and cocaine induce phosphorylation of DARPP-32 at 
Thr
34
 and dephosphorylation at Thr
75
. In addition to dopamine, DARPP-32 is 
regulated by e.g. serotonin and glutamate, which is why different drugs of abuse 
may have different effects on DARPP-32 phosphorylation.  
 
The extracellular signal-regulated kinase (ERK1/2), which belongs to the 
MAPK-family, is another important mediator of striatal signal transduction 
downstream from cAMP. ERK1/2 regulates several important cellular functions 
in the brain, including cell differentiation and synaptic plasticity (Thomas and 
Huganir 2004). ERK1/2 is also implicated in drug addiction. In striatal MSNs 
ERK1/2 is activated by many drugs of abuse including cocaine, amphetamine 
and morphine (Valjent, et al 2000; Valjent, et al 2004; Valjent, et al 2006). 
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Although these drugs have different mechanisms of action, they all share the 
property of increasing dopamine release. The regulation of ERK1/2 by drugs of 
abuse involves the cross-talk between the D1R and NMDA glutamate receptors 
(Valjent, et al 2005; Cahill, et al 2014). ERK1/2 phosphorylation can be 
prevented by both D1R antagonists or by knockout of D1R but also by an 
NMDA antagonist. This indicates that ERK1/2 activation requires the 
stimulation of both D1Rs and NMDA receptors. Interestingly, however, 
although ERK1/2 activation is mainly controlled by D1Rs and NMDA 
receptors, there are several other important pathways involved which are, to 
date, far from being fully elucidated. There is for instance evidence, that 
mGluR5 receptors may also activate ERK1/2 (Mao, et al 2005; Voulalas, et al 
2005)     and interestingly, D2R activation also phosphorylates ERK1/2 (Yan, et 
al 1999; Cai, et al 2000; Wang, et al 2005), via cAMP-independent 
mechanisms. D2R signaling responses may also be mediated by the Gβγ-
subunits, which in turn activate PLC and increase cytoplasmic Ca
2+ 
concentrations in the MSNs (Hernandez-Lopez, et al 2000). Ca
2+ 
has complex 
effects on cell signaling, one of them being activation of Ca
2+
/calmodulin -
dependent protein kinase II (CaMKII) (Beaulieu and Gainetdinov 2011). 
CaMKII can activate ERK1/2 via the Ras-Raf-MEK cascade (Fasano, et al 
2009; Baik 2013). Additionally, PLC regulates diacylglycerol (DAG)-mediated 
activation of PKC. PKC, in turn, is involved in the activation of ERK1/2 
cascade. 
 
As described above, dopamine receptors regulate cAMP-PKA and Ca
2+
 -
dependent pathways through G protein-mediated signaling. However, recent 
research on the field has revealed that dopamine receptors exert their effects 
also through cAMP-independent mechanisms. One of the other pathways 
utilized by at least by D2Rs is termed the AKT-GSK3 signaling cascade 
(Beaulieu, et al 2007). The activation of AKT is initiated via GPCRs and plays 
a key role in multiple cellular processes such as glucose metabolism, apoptosis, 
cell proliferation and transcription. AKT is a serine/threonine-specific protein 
kinase that is regulated through P13K-mediated signaling (Scheid and 
Woodgett 2001). The dopaminergic activation of AKT-GSK3 signaling 
pathway is independent of cAMP but requires the recruitment of the 
multifunctional adaptor proteins termed arrestins (Beaulieu and Gainetdinov 
2011). β-arrestin 2 (β-Arr2) has been shown to act as a signaling intermediate in 
the AKT-GSK3-pathway. Upon D2R activation β-Arr2 forms a protein complex 
with protein phosphatase 2A (PP2A). Activation of AKT inhibits glycogen 
synthase kinases-3α (GSK3α) and -3β (GSK3β). GSK3α and GSK3β are closely 
related kinases which were originally associated with the regulation of glycogen 
synthesis in response to insulin (Frame and Cohen 2001). However, more 
recently their functions in e.g. cell proliferation, cell differentiation and 
apoptosis have been acknowledged.  
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Originally, the role of AKT-mediated responses in dopaminergic cell signaling 
was observed in mice lacking DAT (DAT KO mice) (Beaulieu, et al 2004; 
Beaulieu, et al 2006). It was found that the persistently elevated extracellular 
dopamine in DAT KO mice leads to reduction of AKT phosphorylation and 
concomitant activation of both GSK3α and GSK3β in the striatum. In addition, 
D2R antagonist haloperidol induces AKT phosphorylation and inhibition of 
GSK-3 and individuals with schizophrenia have lower AKT levels in the frontal 
cortex (Emamian, et al 2004). Additionally, AKT KO mice display increased 
sensitivity to the sensorimotor gating -disruptive effect of amphetamine, further 
supporting the role of AKT in the symptoms related to e.g. schizophrenia.  
 
 
 
Figure 5. Signaling pathways mediated via D1Rs and D2Rs. Abbreviations: 
AC, adenylyl cyclase; AKT, protein kinase B; βArr2, β-arrestin 2; CaMKII, 
Ca
2+
/calmodulin -dependent protein kinase II; cAMP, cyclic AMP; CREB, 
cAMP response element-binding protein; DAG, diacylglycerol; DARPP-32, 
dopamine-and cAMP-regulated phosphoprotein; ERK 1/2, extracellular signal-
regulated kinase 1/2; GSK3, glycogen synthase kinase 3; IP3, inositol 
trisphosphate 3; PI3K, phosphatidylinositol 3-kinase; PKA, protein kinase A; 
PKC, protein kinase C; PLC, phospholipase C; PP1, protein phosphatase 1; 
PP2A, protein phosphatase 2A; STEP, striatal-enriched protein tyrosine 
phosphatase 61. For a detailed description of these pathways see: Baik 2013, 
Beaulieu, et al 2007, Beaulieu and Gainetdinov 2011, Girault 2012. 
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2.4.3 Drug addiction 
 
It was first found already in 1950’s that electrical stimulation in the septal area 
(medial olfactory area) of the rat was rewarding (Olds and Milner 1954). Later, 
it became apparent that dopamine has a crucial role in the intracranial self-
administration in the ventral tegmentum, nucleus accumbens and medial PFC 
(Phillips and Fibiger 1978; Fibiger and Phillips 1988). These groundbreaking 
studies have paved the way for understanding the reward circuit in the brain, 
although it is still far from being understood with all its complexities. However, 
dopamine is recognized as one of the most important neurotransmitters in the 
field of addiction due to its crucial role in motivational control (Wise and 
Rompre 1989). In spite the fact that different drugs of abuse act through 
different mechanisms, virtually all abused drug share the property of increasing 
dopaminergic activity acutely (Di Chiara and Imperato 1985; Di Chiara and 
Imperato 1986; Imperato, et al 1986). In line with this, dopamine antagonists 
block the maintenance of self-administration of drugs of abuse (Yokel and Wise 
1976; Bergman, et al 1990). 
 
The mesolimbic dopamine system is the best-characterized reward circuit in the 
brain (Wise 1998; Wise 2002). However, the reward circuitry includes many 
other neurotransmitter systems in addition to dopamine. For example, the 
striatum receives histaminergic innervation from the TMN and dense 
glutamatergic innervation from the PFC, amygdala and hippocampus. The 
functional output from these brain regions is also regulated by both GABAergic 
and cholinergic interneurons. In addition, all these structures receive both 
serotonergic and noradrenergic input from the raphe nuclei and locus coeruleus, 
respectively.  
 
The dopaminergic neurons have two distinct modes; the tonic and phasic 
dopaminergic transmission (Grace 1991). In the tonic mode, dopamine neurons 
have a steady, basal activity (2-10 Hz) that is vital for the function of their 
downstream neural structures (Schultz 2007). In the phasic mode, the 
dopaminergic neurons rapidly increase or decrease their firing for 100-500 ms 
that induces substantial changes in the dopamine concentrations of the 
downstream structures (Schultz 1998; Schultz 2007). The dopaminergic burst 
spiking phasic mode can lead up to 15-30 Hz spiking and is triggered by for 
example by rewards and reward-related sensory cues (Schultz, et al 1997; Wise 
2004; Schultz 2007). The phasic dopaminergic responses are therefore thought 
to play an important role in dopamine-driven motivational control and 
reinforcement.  
 
Chronic use or administration of drugs of abuse leads to long-term adaptive 
changes in the neurochemistry of the brain, including alterations in the gene 
expression (Freeman, et al 2008; Schmidt, et al 2012). Additionally, chronic 
use may induce changes in the anatomy of the brain, especially in the 
morphology of the dendritic spines (Robinson, et al 2001; Robinson, et al 2002; 
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Crombag, et al 2005). These long-lasting alterations may underlie some of the 
persistent psychomotor, cognitive and motivational consequences of chronic 
drug exposure. 
 
 
 
2.5  The interaction between the H3R and the dopaminergic 
system 
 
Interestingly, both histaminergic and dopaminergic systems are involved the 
pathophysiology of several neurological and psychiatric disorders, including 
Parkinson’s disease, Tourette syndrome and addiction (Panula and Nuutinen 
2013). Clarifying histamine-dopamine interactions in the striatum may shed 
new light on understanding the function of these circuits and may provide a 
more comprehensive view on the pathophysiology of several disorders. The 
evidence for histamine-dopamine interaction involves mainly H3Rs and 
dopamine receptors, which is not surprising, considering that these receptors are 
all highly expressed in the striatum and the majority of the striatal D1R- or 
D2R-containing MSNs coexpress H3Rs (González-Sepúlveda, et al 2013).     
  
2.5.1 H3R-mediated dopamine and GABA release 
 
The first evidence of H3R-dopamine interaction arose from a study where it 
was shown that histamine inhibits dopamine release in the mouse striatum via 
presynaptic H3Rs (Schlicker, et al 1993) suggesting that H3R would be located 
on the dopaminergic nigrostriatal nerve terminals. Furthermore, H3R activation 
by immepip inhibits dopamine synthesis in rat striatum (Molina-Hernandez, et 
al 2000). Both histamine and H3R agonist immepip have also been shown to 
inhibit D1R-dependent [3H]-GABA release from rat striatal slices and the 
inhibitory effects of both histamine and immepip can be reversed by the H3R 
antagonist thioperamide  (Arias-Montano, et al 2001). In addition, immepip 
inhibits, in a concentration-dependent manner, D1R agonist SKF-81297-
induced cAMP accumulation in striatal slices (Sanchez-Lemus and Arias-
Montano 2004). 
 
An interesting feature of H3R antagonists is their ability to increase the release 
of dopamine in the PFC and other cortical areas (Schlicker, et al 1994; Fox, et 
al 2005; Medhurst, et al 2007; Southam, et al 2009),  but not to affect the 
striatal dopamine release (Fox, et al 2005; Giannoni, et al 2010; Galici, et al 
2011; Schwartz 2011). Considering, that the striatal H3Rs are mainly located 
postsynaptically on the MSNs, this is not surprising. As already described 
earlier, the vast majority of both D1R (95 %) and D2R (89 %) containing 
striatal neurons also contain H3Rs (Moreno, et al 2011; González-Sepúlveda, et 
al 2013). 
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On the other hand, both D2Rs and H3Rs are coupled to Gαi/o protein in the 
indirect MSN pathway, which might also lead to co-operation of these two 
receptors, whereas in the direct pathway D1Rs is coupled to Gαs protein, 
possibly leading to opposing effects compared to those of H3Rs. In support of 
this, both D2R and H3R agonist decreased striatal GABA release, whereas D1R 
agonist increased it (Arias-Montano, et al 2001). The study was performed in 
dopamine-depleted, reserpinized rats, thus indicating that the demonstrated 
effects arose from the postsynaptic site. Thus, the striatal H3R potentiates the 
D2R-mediated inhibition of the indirect pathway and hinders the D1R-mediated 
excitation of the direct pathway.  
 
2.5.2 H3R-containing heterodimers 
 
The interaction between the H3R and dopamine receptors is much more 
complex than described above, as recent evidence have demonstrated that both 
D2Rs (Ferrada, et al 2008) and D1Rs (Ferrada, et al 2009) may form functional 
heterodimers with H3Rs. The existence of H3R-D2R heterodimers was 
demonstrated in vitro in co-transfected cells and further supported by membrane 
competition experiments, where it was shown that several H3R agonists 
significantly decreased the affinity of D2R agonist (Ferrada, et al 2008). 
Indirect functional evidence from behavioral studies also support the presence 
of D2R-H3R heterodimers in vivo (Pillot, et al 2002; Ferrada, et al 2008).  
 
The existence of D1R-H3R heterodimers was also first demonstrated on co-
transfected cells in vitro (Ferrada, et al 2009). It was shown that H3R activation 
leads to diminished D1R agonist binding and to a significant change in the 
affinity of the D1R. Interestingly, it was also found that when H3R dimerizes 
with D1R, there is a switch to Gαi/o-coupling, whereas under normal conditions 
D1R is coupled to AC via Gαs protein. The consequence is that whereas 
normally dopamine activates the direct pathway via D1Rs, in the presence of 
D1R-H3R heterodimers it inhibits this pathway. Thus, an antagonist of one of 
the receptor of the D1R-H3R heterodimer can induce conformational 
adaptations and inhibit the specific signals. The existence of D1R-H3R 
heterodimers has also been demonstrated in striatal slices suggesting that these 
heterodimers are also present in vivo (Moreno, et al 2011). Moreover, in striatal 
slices H3R activation by imetit leads to activation of ERK1/2 only when the 
D1R is expressed, but not in D1R deficient mice. This indicates that in the 
striatum ERK1/2 phosphorylation induced by H3R activation is mediated by 
D1R-H3R heterodimers. However, the prevalence and significance of either 
D2R-H3R or D1R-H3R striatal heterodimers in vivo is currently not known, as 
is not known to what extent these heterodimers contribute to the dopaminergic 
regulation in general.  
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3. AIMS OF THE STUDY 
 
 
Previous studies have demonstrated that neuronal histamine and H3R might be 
involved in the behavioral effects of drugs of abuse. The major goal of this 
thesis was to clarify the role of histamine and especially H3R in alcohol-related 
behaviors and to investigate the interaction between the histaminergic and 
dopaminergic systems.  
 
 
The specific topics that were studied in this thesis were the following: 
 
 
1. The role of H3R in alcohol consumption and in the motor-impairing 
 and rewarding effects of alcohol 
 
2. The role of histamine in alcohol consumption and in the H3R-mediated 
 inhibition of alcohol reward 
 
3. The role of H3R in the place conditioning by dopaminergic drugs and 
 in their  motor effects  
 
4.  The role of histaminergic system in sensorimotor gating  
 
5.  The interaction between the histaminergic and dopaminergic systems 
 on both transcriptional and signal transduction level 
 
 
  
37 
 
4. MATERIALS AND METHODS 
 
The materials and methods of this thesis work are described in greater detail in 
the original publications (I-V). Only the methods that the candidate has 
personally conducted are shortly described in the following chapter. For the 
supplier information of materials including reagents, drugs and equipment the 
reader is referred to the original publications. 
 
 
4.1 Experimental animals 
 
The principles of the Finnish Act on the Use of Animals for Experimental 
Purposes were followed in conducting these studies and the protocols were 
approved by the National Animal Experiment Board of Finland. For ethical use 
of laboratory animals, the Russell and Burch’s principle of the 3Rs 
(replacement, reduction and refinement) was applied (Russel and Burch, 1959). 
 
 
4.1.1 Genetically modified mouse strains 
 
Both female and male mice were used in the studies where genetically modified 
mice were used. The genotypes of the mice were verified by DNA purification 
followed by PCR amplification before all experiments. Inbred WT and HDC 
KO mice in 129/Sv background were used in CPP, two-bottle choice test, 
locomotor stimulation, radioactive in situ hybridization and in plasma alcohol 
concentration measurements. The generation of HDC gene deletion has been 
described in detail (Ohtsu, et al 2001). Briefly, linearized targeting construct 
was electroporated into R1 embryonic stem cells (ES cells) that were originally 
derived from 129/Sv mouse embryo (Nagy, et al 1993). The chimeric mice, 
generated with the confirmed embryonic stem cells, were then crossed with 
129/Sv mice to obtain the inbred heterozygous (+/−) mice. HDC KO mice were 
a gift from Prof. Hiroshi Ohtsu and were bred in heterozygous crosses in these 
experiments. After being backcrossed to the C57BL/6J background strain in our 
laboratory, HDC KO and WT mice were used in the DID paradigm as this 
protocol is developed for C57BL/6J mice due to their high natural alcohol 
drinking preference (Rhodes, et al 2005). Single nucleotide polymorphism 
analysis was used to analyze that the strains had at least 99.5 % identity with 
C57BL/6J. This background strain was also used in the PPI study. 
 
H1R KO mice were a gift from Prof. Takeshi Watanabe and they were 
generated in the Riken Research Center for Allergy and Immunology by 
homologous recombination (Inoue, et al 1996). Briefly, linearized targeting 
vector was electroporated in E14 ES cells and ES cells carrying the H1R 
mutation were injected into blastocysts from C57BL/6 mice and the resulting 
male chimeras were mated with C57BL/6 mice. 
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Male H3R KO mice were originally supplied by Janssen Research & 
Development, LLC (La Jolla, CA, USA). They were generated on a background 
of 129/Ola and C57BL/6J mice (Toyota, et al 2002). Selective backcrossing 
was conducted in Janssen over 10 generations leading to at least 99.5 % genetic 
identity to C57BL/6J mice. 
 
 
4.1.2 Commercially available mouse strains 
 
In the pharmacological studies where exclusively commercial, inbred WT mice 
were used, only male mice were studied. Inbred WT JAX®DBA/2J mice were 
delivered from Charles River and C57BL/6J mice were delivered from Harlan 
Laboratories at the age of 4-8 weeks. Mice were let to habituate with the change 
of the environment and new facility at least two weeks before starting the 
experiments. 
 
 
4.1.3 Drug treatments 
 
Drugs including alcohol were diluted with sterile saline (0.9 % NaCl) and 
injections were given intraperitoneally (i.p.) with an injection volume of 10 
ml/kg. All drug doses correspond to the free bases of the drugs. Drinking 
solutions were prepared in cold tap water. 
 
 
 
4.2 Behavioral studies 
 
4.2.1 Locomotor activity assessment 
 
The locomotor activity was assessed using an empty cage, where the animal 
could freely move throughout the experiment. The activity of the mice was 
monitored using a video camera and Ethovision® software. Animals were 
brought to the experiment room 30 minutes prior to the start of the experiment. 
They were then placed individually to the empty plastic cages (40 x 26 x 20 cm) 
and habituated to the novel environment for 30-90 minutes depending on the 
experiment. After the habituation period animals received the studied drugs and 
were returned to the test cages for further analysis of locomotor activity. 
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4.2.2 Balance beam 
 
The balance beam experiment was used to study alcohol-induced motor 
impairment. Mice were trained to walk along a wooden beam (100 cm long, Ø 
1.5 cm) placed at 80 cm height from the floor. Training was done three times 
during two consecutive days. On the experiment day the baseline performance 
of the mice was tested. H3R ligands were injected 25 minutes prior to the 
alcohol treatment. The possible effect of the pretreatment on the balance beam 
performance was tested before alcohol injection. The performance on the 
balance beam was tested again 10 minutes after alcohol injection (1.2 g/kg). 
The time to cross the beam was manually recorded with a timer. The mouse 
behavior during the test was recorded by a digital video camera and the number 
of foot slips was later measured from the video. 
 
 
4.2.3 Rotarod 
 
Alcohol-induced motor impairment was also assessed using the accelerating 
rotarod method. Mice were trained daily (three training sessions in the morning, 
three training sessions in the afternoon) to run on an accelerating (5-30 rpm, Ø 
3 cm) rotarod for three minutes until all animals learned the task. The training 
period lasted for seven consecutive days. The latency to fall from the rotating 
rod was manually recorded, and the daily average performance was calculated 
for each animal. On the experiment day, the baseline performance on the 
rotarod was first tested and the mice were then given pretreatment with the H3R 
ligand. The possible effect of pretreatment on rotarod performance was tested 
30 minutes later. Thereafter, alcohol (1.5 g/kg) was administered and five 
minutes later the performance on rotarod was tested again. Immediately after, 
animals received a second alcohol injection (0.5 g/kg) and the motor 
performance was tested again after five minutes. 
 
 
4.2.4 Place conditioning 
 
The CPP paradigm was used as a model for reward and reinforcement. It 
followed the principles of an unbiased, counterbalanced conditioning 
(Cunningham, et al 2006). Metal grid and plastic mat were used as tactile 
conditioning cues on the cage floors. The preference for the conditioning cues 
was tested prior to the experiments and no bias towards either of the floor 
materials was observed. The activity of the mice was recorded in each phase 
using a video camera attached to the Ethovision® software. Briefly, on the first 
day the mice were habituated with the procedure. Mice were weighted, given a 
saline injection according to their weight and placed into an empty conditioning 
cage for 5-30 minutes (five minutes in alcohol-CPP, 30 minutes in quinpirole-
CPA and amphetamine-CPP). The conditioning sessions were conducted on the 
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following days. Mice were randomly assigned to the conditioning subgroups 
(metal or plastic cue). Mice in the metal cue -subgroup received the test drug 
(alcohol, quinpirole or amphetamine) paired with metal cue and saline paired 
with the plastic cue on alternating days. Mice in the plastic cue -subgroup 
received the test drug paired with the plastic cue and saline paired with the 
metal cue. H3R antagonists were administered 30 minutes prior to the test drug. 
Each mouse went through four to six 5-30 minutes long conditioning trials of 
both types (test drug and saline) on alternating days.  The place preference test 
was carried out 24 hours after the last conditioning session. Immediately after 
saline injection mice were placed in the center of the cage in which they had 
free access to both metal and plastic cues. Time spent on different 
compartments of the cage during 15-30 minutes and the total distance moved 
were analyzed from the recorded data. Time spent on the metal compartment 
was used as a primary dependent variable in the data analysis. 
 
 
4.2.5 Drinking in the dark  
 
Alcohol consumption of H3R KO, HDC KO and WT mice (C57BL/6 
background) was studied using the DID procedure with minor modifications 
(Rhodes, et al 2005). The DID paradigm can be used to study binge-like alcohol 
drinking in non-dependent mice. The light–dark cycle was reversed two weeks 
prior the experiment and the mice were single-housed for one to two weeks 
before the beginning of the experiment. In brief, two to three hours after the 
beginning of the dark period, water bottles were replaced with a graduated tube 
containing 20 % (v/v) alcohol and left in place for four hours. Control animals 
received 3-10 % (w/v) sucrose. The volume of alcohol and sucrose consumed 
was recorded two and four hours after the beginning of each drinking session. 
The alcohol consumption was converted to g/kg taking into account the density 
of alcohol (0.7894 g/cm
3
) and the body weight of each animal. 
 
 
4.3  Biochemical studies 
 
4.3.1 Plasma alcohol concentration measurement 
 
The plasma alcohol concentrations were studied in DBA/2J mice after 
pretreatment with H3R ligands followed by alcohol administration. 
Pretreatment was given 30 minutes prior to alcohol. Animals were euthanized 
by carbon dioxide (CO2) 10, 20,100 or 150 minutes after alcohol injection and 
blood samples were collected via heart puncture. Samples were also collected 
from H3R KO and WT mice five minutes after alcohol injection and after the 
last DID session. Additionally, samples were collected from HDC KO and WT 
mice 10, 20, 100 and 150 minutes after alcohol injection.  Blood was collected 
to cold lithium-heparin tubes and centrifuged at 20 000g for two minutes. 
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Plasma samples were then transferred to clean tubes and kept at -80ºC until 
analyzed. A commercial enzyme assay was carried out to measure the alcohol 
concentrations of the plasma samples. 
 
 
4.3.2 Radioactive in situ hybridization 
 
The mRNA expression of different dopaminergic markers were analyzed by 
radioactive in situ hybridization. The detailed description of the radioactive in 
situ hybridization has been described previously (Lintunen, et al 1998). 16-20 
µm cryosections were cut from unfixed, freshly frozen H3R KO, HDC and WT 
mouse brains and kept in a freezer (-80°C) until hybridization. The 
hybridization was carried out using selective and specific oligonucleotide 
probes which were designed using the Eprimer3 software and tested prior to 
experiments. The length of the oligonucleotide probes was 43 bases and the 
nucleotide sequences are presented in Table 2. Each probe was labeled with 
radioactive deoxyATP by using terminal deoxynucleotidyl transferase and 
purified with Sephadex G-50 columns. Sections were covered with the 
hybridization mixture containing 10 000 000 cpm/ml of the labeled, radioactive 
probe. Hybridization was carried out at +45°C for 16 hours. After hybridization, 
the slides were washed with 1 x saline-sodium citrate (SSC) at +55°C for 2 
hours. Next, the sections were dehydrated in a series of alcohol. Dried sections 
were then exposed to films and developed after five to seven days. The 
expression of mRNAs was quantified with MCID4 Image Analysis Software. 
Radiocarbon 
14
C-standard curve was used in the quantification. The results 
analyst was blinded to the genotype of the mouse. Cresyl violet staining was 
carried out in order to select matching striatal sections (Striatum +0.98 mm, 
VTA -3.52 mm from Bregma). 
 
 
Table 2. Nucleotide sequences of the radioactive in situ hybridization probes 
designed by Eprimer3 software. 
 
 mRNA Oligonucleotide sequence 
D1 receptor ATGGACTGCTGCCCTCTCCAAAGCTGAGATGCGCCGGATTTGC 
D2 receptor GCTTTCTTCTCCTTCTGCTGGGAGAGCTTCCTGCGGCTCATCG 
TH GGTAGGTTTGATCTTGGTAGGGCTGCACGGCTGCTGTGTCTGG 
DAT TCAGCCACGCTACAGTCTGCAGAGCCAACAGGCCTGCATTTCC 
STEP61 AGGTATTCATGGGCTGACTCCTCTCGTGGGGACACCAGGTAGC 
DARPP-32 (2 probes 
combined) 
CCACACTCACTGGCGATCCCCGGATGTCAACTTCTGTCAGACC and 
GCTGGCTCCTTGGGAATCCAGTGGTAGCATGTGGGCTGAAAGG 
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4.3.3 Semi-quantitative Western blotting 
 
Dopaminergic cell signaling was studied in H3R KO and WT mice by Western 
blotting. Mice were injected with saline, D1R agonist SKF-38393 or D2R 
agonist quinpirole and decapitated 20 minutes after drug injections. Prefrontal 
cortices (~1.5-3.5 mm from Bregma) and striata (~0.5-1.5 mm from Bregma) 
were dissected on ice, immediately freezed and kept in a freezer (-80°C) until 
analyzed. Samples were weighted and homogenized in lysis buffer by 
sonication. Homogenates were centrifuged (five minutes at 20 000g), and the 
protein concentration of the supernatant determined by Bio-Rad Protein assay. 
Samples (40-50 µg of total protein/well) were separated based on protein size 
by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and 
transferred to a nitrocellulose membrane with eBlot® protein transfer system. 
Phosphorylated forms of ERK1/2 and AKT were detected with the mouse anti-
phospho-ERK1/2 and rabbit anti-phospho-AKT primary antibodies. The 
unphosphorylated forms of the corresponding proteins were detected with rabbit 
anti-ERK1/2 and rabbit anti-AKT primary antibodies. All primary antibodies 
were manufactured by Cell Signaling and used at dilutions 1:1000. The signal 
was detected using infrared-labeled secondary antibodies at dilutions 1:10 000-
1:30 000. For monoclonal primary antibodies goat anti-mouse IgG1 and for 
polyclonal primary antibodies goat anti-rabbit were used. The signal was 
detected using Odyssey® Imaging System and quantified with the LI-COR 
Image Studio software. The values were corrected by dividing the signal 
intensity of the phosphorylated protein with that of the corresponding 
unphosphorylated protein. 
 
 
4.4  Data analysis 
 
Statistical analyses were performed using GraphPad Prism 4 software. The 
Student’s t-test was applied in comparison between two groups. Data containing 
more than two groups with only one variable was analyzed by one-way analysis 
of variance (ANOVA) followed by Tukey’s or Newman-Keuls post-hoc tests. 
Data with two variables was analyzed by two-way ANOVA followed by 
Bonferroni’s post-hoc test. P<0.05 was considered significant. The results in 
graphs are expresses as mean ± standard error of the mean (SEM).   
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5. RESULTS  
 
For more detailed description of results and statistical analysis of the data, the 
reader is referred to the original publications (I-V). The main behavioral results 
of this thesis work are combined in Tables 3, 4 and 5.  
 
 
5.1  H3R in alcohol-related behaviors 
 
 
5.1.1 H3R in CPP (I-III) 
 
Ciproxifan (3 mg/kg), JNJ-10181457 (5 mg/kg) and JNJ-39220675 (0.3 mg/kg) 
inhibited the development of alcohol-induced place preference (alcohol-CPP, 2 
g/kg) in DBA/2J mice (Figure 1B in publication I, Figure 1A in III). 
Surprisingly, higher doses of JNJ-10181457 (10 mg/kg) and JNJ-39220675 (3 
mg/kg and 10 mg/kg) had no effect on the development of alcohol-CPP (Figure 
1A in publication III), indicating that only low doses of H3R antagonist are 
effective in blocking the rewarding properties of alcohol. H3R KO (in 
C57BL/6J background) did not develop alcohol-CPP (Figure 4B in publication 
II). 
 
 
5.1.2 H3R in alcohol consumption (II) 
 
In the two-bottle choice paradigm H3R KO mice consumed less alcohol (10 and 
20 %) than the control mice (Figure 1A in publication II). There were no 
differences between the genotypes in the consumption of 3 or 6 % alcohol. In 
addition, in the DID paradigm H3R KO mice consumed less alcohol (20 %) 
(Figure 2A,B and C). Additionally, H3R antagonist ciproxifan (0.3, 1, 3 mg/kg) 
decreased alcohol (20 %) consumption in the DID model ((Figure 3A), whereas 
H3R agonist immepip (30 mg/kg) increased alcohol drinking in C57BL/6J mice 
(Figure 3C). Taken together, H3R KO mice consumed less alcohol in both 
voluntary and binge-like drinking paradigms compared to WT mice. In the 
binge-like drinking paradigm 
 
 
5.1.3 H3R in alcohol-induced motor functions (I-III) 
 
Ciproxifan (3 mg/kg) had no effect on the alcohol-induced locomotor 
stimulation when alcohol was injected at a dose 1.5 g/kg in either DBA/2J 
(Figure 2A and B in publication I) or in 129/Sv mice (Figure 4A in publication 
III). However, ciproxifan increased and extended alcohol stimulation, when a 
lower dose of alcohol (1 g/kg) was given to DBA/2J mice (Figure 2C and D in 
publication I). Ciproxifan did not alter the motor-impairing effects of alcohol in 
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neither balance beam nor rotarod, but H3R agonist immepip (10 mg/kg) further 
impaired the performance on the balance beam after alcohol (1.2 g/kg) as 
measured by the number of foot slips (Figure 3 in publication I). H3R KO mice 
were less stimulated by alcohol (1.5 g/kg) indicated by the lower distance 
moved compared to controls (Figure 5A and B in publication II) and less 
sensitive to the motor-impairing effects of alcohol, as measured by the number 
of foot slips on the balance beam (Figure 5F in publication II). JNJ-39220675 
had no effect on alcohol-induced (1 or 1.5 g/kg) stimulation in DBA/2J (Figure 
1C in publication III) or 129/Sv mice (Figure 4C in publication III). In DBA/2J 
background strain all three pretreatment doses of JNJ-39220675 (0.3, 3 and 10 
mg/kg) were tested, whereas in 129/Sv we tested two doses of JNJ-39220675 
(0.3 mg/kg and 10 mg/kg). 
 
 
5.2  Histamine in alcohol consumption, stimulation and reward 
(III) 
 
HDC KO mice consumed as much alcohol as the WT control mice in both 
drinking paradigms used in these studies: the two-bottle choice and the DID. 
HDC KO and their WT control mice in the two-bottle choice paradigm mice 
were in the 129/Sv background strain. There was no differences in the alcohol 
consumption in any of the given alcohol concentrations (3, 6, 10 or 20 
%)(Figure 3A in publication III). After backcrossing the HDC KO mice from 
129/Sv to C57BL/6J background, the mice were used in the DID paradigm, 
which was able to replicate the finding; the lack of endogenous histamine does 
not affect alcohol consumption (Figure 1C and E). In addition, HDC KO mice 
were equally stimulated by alcohol as compared to the WT mice (Figure 4). 
Similarly to WT mice (in 129/Sv background), neither ciproxifan (3 mg/kg) nor 
JNJ-39220675 (0.3 or 10 mg/kg) altered the alcohol-induced stimulation in 
HDC KO mice as measured by the distance moved. Interestingly, in HDC KO 
mice neither ciproxifan (3 mg/kg), JNJ-10181457 (1 and 5 mg/kg) nor JNJ-
39220675 (0.3 mg/kg and 10 mg/kg) inhibited alcohol-CPP (Figure 2A). 
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Table 3. Summary of the behavioral responses of HDC KO mice compared to 
WT mice.  
 
Background 
strain Pretreatment Drug Paradigm Result Ref. 
129/Sv  − Alcohol LMA Stimulation − III 
129/Sv  − Alcohol TBC Consumption  − III 
129/Sv Ciproxifan Alcohol CPP CPP  − III 
129/Sv JNJ-10181457 Alcohol CPP CPP  − III 
129/Sv JNJ-39220675 Alcohol CPP CPP  − III 
129/Sv Ciproxifan Alcohol LMA LMA − III 
129/Sv JNJ-39220675 Alcohol LMA LMA − III 
C57BL/6J  − Alcohol DID Consumption  − III 
C57BL/6J  −  − PPI PPI    − V 
 
Abbreviations: CPP, conditioned place preference; DID, drinking in the dark; 
LMA, locomotor activity; PPI, prepulse inhibition; Ref., reference; TBC, two-
bottle choice. Symbol: − no effect. 
 
 
 
5.3  H3R in the behavioral effects of dopaminergic drugs  
 
 
5.3.1 H3R in the behavioral effects of amphetamine (IV) 
 
Acutely administrated pretreatment with JNJ-39220675 (1 mg/kg and 10 
mg/kg) inhibited locomotor activation induced by amphetamine (2 mg/kg) in 
C57BL/6J mice (Figure 1A in publication IV). Interestingly, when both drugs 
were injected subchronically over four consecutive days, JNJ-39220675 lost its 
inhibitory effect on the amphetamine-induced stimulation (Figure 1B). In other 
words, on the fourth day of conditioning, both doses of JNJ-39220675 
pretreatment combined with amphetamine induced stimulation comparable to 
that of saline-pretreated amphetamine-group. There was a significant 
development of place preference by amphetamine (Figure 1D). JNJ-39220675 
had no effect on place conditioning by amphetamine on either of the doses 
tested (1 mg/kg and 10 mg/kg).  
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5.3.2 H3R in the behavioral effects of quinpirole (IV)  
 
D2R agonist quinpirole (0.5 mg/kg) -treated C57BL/6J mice spent significantly 
more time on the compartment associated with the saline treatment, indicating a 
development of conditioned place aversion (CPA) (Figure 2B in publication 
IV). We next studied, whether the pretreatment with JNJ-39220375 has an 
effect on the development of quinpirole-induced CPA and found that JNJ-
39220675 (10 mg/kg) did not alter the aversive effect of quinpirole. 
 
Quinpirole decreased the mobility of the mice as measured by the distance 
moved, velocity and immobility on the first day of the subchronic treatment 
(Figure 4A,B and C). JNJ-39220675 pretreatment had no effect on the 
quinpirole-induced hypokinesia on the first day. However, the hypolocomotion 
induced by quinpirole was diminished after repeated treatment with quinpirole 
and on the fifth day of administration, the quinpirole-induced activity was no 
longer decreased compared to saline-treated mice. This indicated that mice had 
developed desensitization to the hypokinetic effect of quinpirole. However, 
JNJ-39220675 was able to inhibit the quinpirole-evoked desensitization as 
indicated by the significant difference between the saline + saline -treated and 
JNJ-39220675 + quinpirole -treated mice on the fifth day of administration. 
JNJ-39220675-mediated inhibition of quinpirole-evoked desensitization was 
observed in all parameters analyzed (distance moved, velocity and immobility). 
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Table 4. Summary of H3R antagonists-mediated behavioral responses in 
different background of WT mice. 
 
Background 
strain Pretreatment Drug Paradigm Result Ref. 
129/Sv Ciproxifan Alcohol LMA Stimulation − III 
129/Sv JNJ-39220675 Alcohol LMA Stimulation − III 
DBA/2J JNJ-39220675 Alcohol LMA Stimulation − III 
DBA/2J JNJ-39220675 Alcohol CPP CPP ↓ III 
DBA/2J JNJ-10181457 Alcohol CPP CPP ↓ I 
DBA/2J Ciproxifan Alcohol CPP CPP ↓ I 
DBA/2J Ciproxifan Alcohol LMA Stimulation ↑ I 
DBA/2J Ciproxifan Alcohol BB Foot slips − I 
DBA/2J Ciproxifan Alcohol Rotarod Latency to fall  − I 
C57BL/6J Ciproxifan Alcohol DID Consumption ↓ II 
C57BL/6J JNJ-39220675 Amphetamine CPP CPP  − IV 
C57BL/6J JNJ-39220675 Amphetamine LMA Stimulation ↓ IV 
C57BL/6J JNJ-39220675 Amphetamine R-LMA Stimulation  − IV 
C57BL/6J JNJ-39220675 Quinpirole CPA CPA − IV 
C57BL/6J JNJ-39220675 Quinpirole R-LMA Desensitization ↓ IV 
 
Abbreviations: BB, balance beam; CPA, conditioned place aversion; CPP, 
conditioned place preference; DID, drinking in the dark; LMA, locomotor 
activity; PPI, prepulse inhibition; Ref., reference; R-LMA, locomotor activity 
after repeated administration. Symbols: − no effect; ↑ increased effect; ↓ 
decreased effect. 
 
 
5.3.3 H3R in D1R and D2R agonist-induced stimulation 
(V) 
 
The basal locomotor activity did not differ between H3R KO and WT mice. 
Surprisingly however, a high dose of amphetamine (5 mg/kg) induced a 
stronger stimulation in the H3R KO mice as compared to the controls (Figure 
2A and B in manuscript V). D1R agonist SKF-38393 (10 mg/kg) induced a 
long-lasting (about two hours) and equal stimulation in both H3R KO and WT 
mice. (Figure 3E and F).  We observed that the effect of quinpirole (0.5 mg/kg) 
on locomotion has two phases, and the biphasic effect of quinpirole on 
locomotor activity has also been previously published (Eilam and Szechtman 
1989; Van Hartesveldt 1997). The first hypolocomotor phase lasts about two 
hours and is followed by the second phase, a moderate stimulation in WT mice. 
Here we observed that the stimulatory effect of quinpirole did not occur in the 
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absence of H3R as no biphasic effect of quinpirole was observed in the H3R 
KO mice (Figure 2C and D). This was observed in both parameters analyzed: 
the distance moved and the velocity.  
 
 
5.4  Histamine, H1R and H3R in sensorimotor gating (V) 
 
Before the actual PPI experiment, the startle responses were examined by 
exposing the animals to sounds of different intensity (dB). We observed no 
differences in the startle amplitudes between the genotypes in HDC KO and 
WT (Figure 1E in manuscript V) and H3R and WT mice (Figure 1A). However, 
the startle responses were significantly lower in the H1R KO compared to the 
control mice (Figure 1G). Interestingly, we found that H3R KO displayed 
impaired sensorimotor gating as measured by the PPI ((Figure 1B). To further 
investigate the mechanism, we selected two pharmacological ligands D2R 
antagonist and NMDA antagonist, to enhance and decrease the PPI responses.  
D2R antagonist haloperidol (0.75 mg/kg) was able to restore the impaired PPI 
to the normal level in the H3R KO mice ((Figure 1C), whereas the NMDA 
antagonist MK-801 (1 mg/kg) decreased the PPI responses in both H3R KO and 
WT mice (Figure 1D). No significant differences in the PPI responses were 
observed between HDC KO and WT (Figure 1F) and H1R KO and WT mice 
(Figure 1H). As there were no differences between the genotypes, no 
pharmacological treatments were further tested in these mouse strains. 
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Table 5. Summary of the behavioral responses of H3R KO compared to WT 
mice (in C57BL/6J background strain). 
 
Drug Paradigm Result Ref. 
Alcohol CPP CPP ↓ II 
Alcohol LMA Stimulation ↓ II 
Alcohol DID Consumption ↓ II 
Alcohol TBC Consumption ↓ II 
Alcohol BB Foot slips ↓ II 
Alcohol Rotarod Latency to fall  − II 
Amphetamine LMA Stimulation  ↑ V 
Quinpirole LMA Stimulation ↓ V 
SKF-38393 LMA Stimulation − V 
− PPI PPI  ↓ V 
Haloperidol PPI PPI ↑ V 
MK-801 PPI PPI   − V 
 
Abbreviations: BB, balance beam; CPP, conditioned place preference; DID, 
drinking in the dark; LMA, locomotor activity; PPI, prepulse inhibition; Ref., 
reference;  Rotarod, rotating rod; TBC, two-bottle choice. Symbols: − no effect; 
↑ increased effect; ↓ decreased effect. 
 
 
 
5.5  Biochemical effects of histamine and H3R 
 
 
5.5.1 Plasma alcohol concentrations (I-III)  
 
Neither imidazole-based ciproxifan (3 mg/kg) nor immepip (30 mg/kg) 
pretreatment had an effect on plasma alcohol concentration 15 minutes after 
alcohol (1.5 g/kg) was administered (in text in publication I). Neither did the 
non-imidazole based JNJ-39220675 (0.3, 3 or 10 mg/kg) have an effect on 
plasma alcohol concentration at any measured time point (10, 20,100 and 150 
minutes after 2 g/kg alcohol injection) (Figure 1C in publication III). There was 
no difference between plasma alcohol concentrations five minutes after alcohol 
injection in H3R KO mice compared to WT controls (in text in publication II). 
Neither was there a difference in plasma alcohol concentrations in HDC KO 
mice compared to WT animals (10, 20,100 or 150 minutes after 2 g/kg alcohol 
injection) (Figure 2B in publication III).  
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5.5.2 Expression of dopaminergic markers in HDC KO 
mice (III) 
 
The quantitative radioactive in situ hybridization was used in order to study 
different dopaminergic signaling components in HDC KO and WT mice 
striatum (+0.98 mm from Bregma). The striatum was subdivided into five 
divisions: the dorsolateral caudate putamen (DL CPu), dorsomedial caudate 
putamen (DM CPu), ventral caudate putamen (V CPu), nucleus accumbens core 
(AcbC) and nucleus accumbens shell (AcbSh). Of these the DL CPu, DM CPu 
and V CPu represent the dorsal striatum whereas the AcbC and AcbSh represent 
the ventral striatum. No differences were observed in the mRNA expression 
levels of D1R, D2R, striatal-enriched protein tyrosine phosphatase 61 (STEP61) 
or DARPP-32 between HDC KO and WT mice in any of the striatal 
subdivisions (Table 1 in publication III). 
 
 
5.5.3 Expression of dopaminergic markers in H3R KO 
mice (V) 
 
The expression of D1R and D2R mRNA analyzed from the striatal subdivisions 
described in the previous chapter (+0.98 from Bregma). TH and DAT were 
analyzed from the VTA (-3.52 from Bregma). We found no differences between 
the genotypes in the expression on D2R, TH or DAT mRNA expression (Figure 
5B in manuscript V). However, there was a significant overall difference in the 
mRNA expression of D1R in the striatum, supporting the interaction between 
the H3Rs and D1Rs in the striatum.  
 
 
5.5.4 Dopaminergic signal transduction in H3R KO mice 
(V) 
 
To asses dopaminergic signal transduction in H3R KO and WT mice were 
injected in vivo either with quinpirole or SKF-38393. Dopaminergic signaling 
was investigated by semi-quantitative Western blotting and phosphorylated 
forms of ERK1/2 and AKT were selected as markers of dopaminergic 
activation. Neither quinpirole (Figure 3C and D in manuscript V) nor SKF-
38393 (Figure 4C and D) activated ERK1/2 or AKT in the PFC in either of the 
genotypes. However, in the striatum, both dopaminergic ligands activated 
ERK1/2 in the WT mice (Figure 3A and 4A). Importantly, no striatal activation 
of ERK1/2 was observed in mice lacking H3R (Figure 3B and 4B), indicating 
that H3R is required for both D1R- and D2R-mediated signaling.  
 
 
 
 
51 
 
6. DISCUSSION 
 
 
6.1  H3R in alcohol-related behaviors (I-III) 
 
One of the main aims of this thesis was to study the involvement of the brain 
histaminergic system, especially H3R in alcohol-related behaviors. To 
investigate this, different behaviors were assessed using both pharmacological 
tools and genetically modified mouse models. The CPP paradigm was selected 
as indicator of reward and positive reinforcement. It is a form of Pavlovian 
conditioning and is extensively used to measure the rewarding and motivational 
effects of objects or experiences such as abused drugs (Cunningham, et al 
2006). In this thesis, the mice were conditioned to associate the drug and a 
tactile stimulus and if the drug had a motivational significance, mice spent 
significantly more time in proximity to the drug-associated cue. This was 
considered to represent drug-driven reward and reinforcement as there was no 
bias toward the tactile cues prior to conditioning. We found that pretreatment 
with H3R antagonists ciproxifan and JNJ-39220675 clearly inhibited the 
development of alcohol-CPP in DBA/2J mice, indicative of lack of reward and 
reinforcement by alcohol. Additionally, JNJ-10181457 inhibited alcohol-CPP, 
although its effect was rather weak, although statistically significant. H3R 
agonist immepip did not alter alcohol-CPP. Previous studies have shown that 
H3R antagonists are motivationally neutral and are not rewarding or aversive 
themselves (Munzar, et al 2004; Nuutinen, et al 2010; Uguen, et al 2013). This 
is of great relevance in the drug development and also indicates that the 
inhibitory effect of alcohol-CPP does not arise from aversive response to H3R 
antagonist pretreatment. Nevertheless, the observed inhibition of alcohol-CPP 
by JNJ-10181457 and JNJ-39220675 demonstrated an idiosyncratic dose-
dependence. Surprisingly, only low doses of the antagonists inhibited the 
development of alcohol-CPP whereas the higher doses had no effect. The 
underlying mechanisms remain unclear. Pharmacokinetic interactions are 
unlikely to explain this phenomenon since JNJ-39220675 had no effect on the 
pharmacokinetic profile of alcohol. The possible explanations for the lack of 
dose-dependence are discussed next. 
 
Both JNJ-10181457 and JNJ-39220675 penetrate easily through the blood-brain 
barrier in rat studies carried out in rats. JNJ-39220675 ex vivo H3R occupancy 
reaches the maximal level quickly at both 3 and 10 mg/kg doses in the rat 
striatum, whereas at a dose 0.3 mg/kg the receptor occupancy is about 75-80 % 
and stays on that level for about four hours (Galici, et al 2011). The H3R has 
several different isoforms derived by alternative splicing (Lovenberg, et al 
1999; Drutel, et al 2001; Coge, et al 2001; Rouleau, et al 2004). These different 
H3R splice variants differ in their localization and pharmacological properties 
such as signal transduction efficiencies (Drutel, et al 2001; Hancock, et al 
2003). As the different isoforms of the H3R are heterogeneously distributed in 
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the brain and have different functional properties, it may be that the lower doses 
of H3R antagonists display isoform-specific regulation of different brain 
functions. This isoform-specific regulation might thus partly contribute to the 
findings on this thesis. In the striatum, H3R is located on both presynaptic and 
postsynaptic sites, which might provide another plausible explanation for the 
inhibition of alcohol-CPP only at low doses of H3R. H3R antagonists acting at 
the presynaptic H3R autoreceptors increase histamine release (Arrang, et al 
1983) allowing more histamine to act on the postsynaptic H3Rs located on the 
inhibitory GABAergic MSNs projecting to the globus pallidus and substantia 
nigra regulating the dopaminergic neurons (Pillot, et al 2002). Thus the 
increased release of histamine by H3R antagonists may indirectly inhibit the 
dopaminergic neurons. However, as both histamine and H3R antagonists bind 
to the postsynaptic H3Rs, the outcome is complex. Nevertheless, the diversity 
and complexity of the H3R system provides another plausible explanation for 
the responses seen with different doses of H3R antagonists. 
 
Further supporting the importance of H3R in the regulation of alcohol reward, 
we found that H3R KO mice did not develop alcohol-CPP. Additionally, H3R 
KO were not as stimulated by alcohol as the WT controls and the lack of H3R 
resulted in mild tolerance to the motor-impairing effects of alcohol, as indicated 
by the lower number of foot slips in the balance beam experiment. However, 
the lower motor-impairing effect of alcohol in H3R KO was not observed in the 
accelerating rotarod. We also observed that H3R KO mice consumed less 
alcohol than WT mice (C57BL/6J) in both voluntary two-bottle choice test and 
in the DID model of alcohol drinking. Additionally, ciproxifan was found to 
decrease and immepip to increase alcohol drinking in the DID paradigm. 
Previous studies have also shown that H3R antagonists thioperamide and 
clobenpropit inhibited alcohol drinking in AA rats with a genetic preference for 
alcohol (Lintunen, et al 2001). Our findings were later confirmed in a study 
conducted in rats, where it was shown that JNJ-39220675 decreased alcohol 
consumption in another alcohol-preferring rat (P) line (Galici, et al 2011). In 
mice, a recent study conducted with a novel H3R antagonist ST1283 supports 
the inhibitory role of H3R antagonism on alcohol consumption and reward 
(Bahi, et al 2013). 
 
All abused drugs including alcohol share the property of targeting the midbrain 
dopamine neurons via either indirect or direct actions, leading to an increase in 
the activity of the dopaminergic system. The direct action, by which alcohol 
increases dopaminergic transmission, is not fully known (Sulzer 2011). There is 
some evidence that alcohol might directly excite dopaminergic neurons in the 
VTA (Brodie, et al 1999; Okamoto, et al 2006), but alcohol might also exert its 
effects via disinhibition of dopaminergic neurons as the effects of alcohol are 
partially mediated by GABA receptors (Mereu and Gessa 1985). Regardless of 
the mechanism of increased dopaminergic transmission by alcohol, we 
hypothesized that H3Rs inhibit alcohol-reward and consumption via mechanism 
involving an interaction with the dopaminergic system. This was further studied 
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using both behavioral and mechanistical experiments and will be discussed in 
the following chapters.  
 
 
6.2  Histamine in alcohol-related behaviors (III) 
 
Interestingly, we found that none of the tested H3R antagonists (ciproxifan, 
JNJ-10181457 or JNJ-3922067) were able to inhibit alcohol reward in any 
tested doses in HDC KO mice. It thus seems that H3R antagonists inhibit 
alcohol reward in a histamine dependent manner. In other words, histamine is 
likely to have an inhibitory role in alcohol reward. The major drawback of this 
study, however, is the use of different mouse strains. It is commonly known that 
the background strain has a significant impact on the behavioral responses of 
the mice (Wolfer, et al 2002; Eisener-Dorman, et al 2009). The alcohol-CPP on 
HDC KO mice was conducted before the selective backcrossing to C57BL/6J 
mouse strain, and the mice were thus in 129/Sv background. In the studies were 
we found that ciproxifan, JNJ-10181457 or JNJ-3922067 inhibited alcohol-CPP 
the DBA/2J mouse strain was used, that is the background strain to which the 
alcohol-CPP paradigm was also originally developed (Cunningham, et al 2006). 
In an earlier study conducted in 129/Sv background WT mice it was found that 
ciproxifan increased, rather than decreased, alcohol-CPP (Nuutinen, et al 2010). 
In that study HDC KO mice also displayed enhanced alcohol-CPP. Due to 
different background strains used in these studies, the interpretation of the 
results is difficult. 
 
However, the foremost important finding from the experiments conducted HDC 
KO mice in this thesis arose from the alcohol drinking studies. Considering, that 
histamine is likely to have an inhibitory role in alcohol-CPP, it was surprisingly 
observed in two different background strains that the lack of endogenous 
histamine has no effect on alcohol consumption. If histamine is inhibitory in 
alcohol reward, mice lacking histamine could be expected to consume more 
alcohol than the WT mice. This contradiction may possibly be due to a ceiling 
effect; especially in the binge-like DID alcohol drinking paradigm the alcohol 
consumption is already remarkably high in the control mice and may not be 
further increased. Nevertheless, in the voluntary two-bottle choice drinking 
paradigm the mice were in 129/Sv background strain and no differences were 
observed between the genotypes in alcohol consumption or alcohol preference 
over water in any of the alcohol concentrations studied. Additionally, HDC KO 
mice in C57BL/6J background were used after selective backcrossing in another 
alcohol drinking paradigm. DID paradigm has been developed in the C57BL/6J 
background due to the high alcohol preference of this strain (Rhodes, et al 
2005). Also this study revealed that HDC KO mice consume alcohol similarly 
to the WT mice. These findings together with the studies conducted in H3R KO 
mice, support the hypothesis, that rather than histamine per se H3R in an 
important mediator of alcohol drinking behavior. Additionally, this suggests 
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that H3R has a crucial role in reward and reinforcement induced by alcohol and 
this is likely to involve an interaction with the mesolimbic dopamine system. 
 
 
 
6.3  H3R and behavioral responses of dopaminergic 
drugs (IV-V) 
 
To extend our current knowledge of the role of H3R in addiction, we also 
examined the effects of H3R in the behavioral responses of amphetamine. 
Amphetamine has a large variety of actions on the dopaminergic system, 
including inhibition of DAT, VMAT and MAO (Sulzer 2011). Amphetamine 
has many derivatives including methamphetamine, and these two have similar 
properties in terms of e.g. changes in the dopamine release in the dorsal 
striatum (Melega, et al 1995) and the drugs are not distinguished in human 
discrimination studies (Lamb and Henningfield 1994).  
 
Surprisingly, we found that a high dose of amphetamine (5 mg/kg) induced a 
stimulation of locomotor activity that was higher in H3R KO mice compared to 
control mice. This observation is in contrast with other studies where it has been 
shown that H3R KO mice are less stimulated by methamphetamine (Toyota, et 
al 2002; Okuda, et al 2009). However, the dose of methamphetamine used in 
those studies is relatively low (1 mg/kg) compared to the dose used in our 
locomotor activation experiment (5 mg/kg). Nonetheless, the contradictory 
results may be explained by the original characterization of the H3R KO mice 
where it was observed that mice lacking H3R are less sensitive to 
methamphetamine-induced stereotypies (Toyota, et al 2002). Thus, it is possible 
that amphetamine induced more stereotypies in WT animals which made them 
move less than the H3R KO mice. 
 
We next studied whether H3R antagonism effects amphetamine-induced 
locomotor activation and found that JNJ-39220675 inhibited amphetamine-
induced stimulation acutely but not after repeated administrations. The acute 
inhibition of amphetamine-induced hyperactivity has also been previously 
shown using other H3R antagonists, including thioperamide (Akhtar, et al 
2006), ciproxifan and clobenpropit (Mahmood, et al 2012). However, another 
novel non-imidazole H3R antagonist GSK207040 had no effect on 
amphetamine-induced stimulation in rats (Southam, et al 2009). JNJ-39220675 
does not affect dopamine release in the nucleus accumbens (Galici, et al 2011) 
and thus the inhibitory effect of JNJ-39220675 on the amphetamine-induced 
stimulation is most likely not mediated via H3R-mediated decreased release of 
dopamine. We hypothesize, that JNJ-3922075 inhibits amphetamine stimulation 
by binding to H3Rs on GABAergic MSNs and thereby affects the postsynaptic 
dopaminergic signaling following dopamine release evoked by amphetamine. 
This is further supported by the findings that both D1Rs and D2Rs may form 
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functional heterodimers with H3R on the postsynaptic site by which the 
receptors modulate one another’s actions (Ferrada, et al 2008; Ferrada, et al 
2009; Moreno, et al 2011). The interaction between H3R and dopamine 
receptors, however, is extremely complex and far from being fully understood. 
Nevertheless, this study suggests that H3R antagonist is able to inhibit the 
behavioral effects of dopaminergic activation acutely, possibly by increasing 
D2R affinity and thereby strengthening the Gαi/o protein-mediated inhibitory 
cAMP-signaling of the indirect pathway. 
 
Interestingly, we found that after repeated administrations of the drugs, JNJ-
39220675 lost its inhibitory effect on amphetamine stimulation. On the fourth 
day of the experiment, JNJ-39220675 pretreatment had no effect on 
amphetamine-induced hyperlocomotion. The possible explanations for the lack 
of effect of JNJ-39220675 in repeated administration with amphetamine might 
lie on the upregulation of dopaminergic transmission in response to repeated 
administration of amphetamine. Subchronic amphetamine or methamphetamine 
administration has been shown to induce an increase in D1Rs in the striatum 
and substantia nigra whereas D2R binding has remained unaltered after 
amphetamine treatment (Ujike, et al 1991; Bonhomme, et al 1995; Tomić and 
Joksimović 2000). As the D1R-mediated signaling is increased after repeated 
administration of amphetamine, the role of D2R-mediated signaling is 
presumably decreased, at least partly explaining why H3R antagonism is not 
able to reduce amphetamine stimulation over repeated administration. In 
addition, subchronic administration of amphetamine may also upregulate DAT 
and VMAT2 (Lu and Wolf 1997; Shilling, et al 1997). Thus, the upregulation 
of essential components in the dopaminergic regulation may explain why JNJ-
39220675 lost its inhibitory effect on amphetamine-evoked stimulation over 
repeated administrations.  
 
Because the effects of novel non-imidazole H3R antagonists on amphetamine-
CPP have not been studied, in this thesis we investigated the effect of JNJ-
39220675 on amphetamine reward. Neither of the tested doses (1 and 10 
mg/kg) of JNJ-39220675 had an effect on the development of amphetamine-
CPP. In agreement with this, methamphetamine-induced CPP was not altered in 
H3R KO mice (Okuda, et al 2009). However, these studies are in contrast with 
other studies where H3R antagonists have been shown to potentiate 
psychostimulant-induced behaviors. Thioperamide has been shown to potentiate 
cocaine-induced CPP (Brabant, et al 2005) and both clobenpropit and 
thioperamide potentiate methamphetamine self-administration (Munzar, et al 
2004). However, it has been proposed that the potentiation of reward and self-
administration are due to pharmacokinetic interaction leading to decreased 
metabolism of psychostimulants followed by potentiated behavioral responses 
(Panula and Nuutinen 2013). Nevertheless, as already discussed above, 
amphetamine has a wide range of effects on the presynaptic dopamine 
transmission (Sulzer 2011) and it is likely that H3R antagonism is not enough to 
modulate all these effects and cannot thus inhibit the rewarding properties of 
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amphetamine. However, it would be interesting to study whether H3R 
antagonism plays a role in amphetamine-induced withdrawal or relapse.  
 
In order to study whether H3R regulates the locomotor responses of specifically 
dopamine receptor targeting drugs, we used both D1R-like agonist SKF-38393 
and D2R-like agonist quinpirole. The stimulatory response of SKF-38393 has 
been reported earlier in C57BL/6J mice (Tirelli and Terry 1993) and in this 
study it was found to be similar in both H3R KO and WT mice. Quinpirole, 
however, has been reported to have variable effects on locomotion and other 
behaviors depending on the species and strains used and these differences might 
reflect distinguishable characteristics in the functional properties of the 
dopaminergic systems between species and strains (Shannon, et al 1991; 
Halberda, et al 1997). In agreement with our findings, however, the biphasic 
effect of quinpirole on locomotor activity has been observed previously. In the 
first phase there is a distinct decrease of locomotion which is later followed by 
hyperlocomotion after about 60-80 minutes of drug administration (Eilam and 
Szechtman 1989; 1994; Van Hartesveldt 1997). In this thesis we found that the 
latter activation of quinpirole was significantly lower in H3R KO compared to 
WT mice. It is not known what causes the biphasic effect but it is possible that 
the latter effect of quinpirole, the locomotor stimulation, is a response of 
quinpirole acting on the postsynaptic D2Rs or perhaps binding of quinpirole on 
the autoreceptors begins to decrease, leading to a release of dopamine. On 
reserpinized mice it has been show that quinpirole induces hyperlocomotion 
already during the first hour after drug administration (Ferrada, et al 2008) 
suggesting that depletion of endogenous dopamine together with postsynaptic 
D2R activation induce locomotor stimulation. This suggests that the 
hypolocomotion seen in normal WT mice immediately after quinpirole 
treatment is an outcome of the presynaptic activation of D2Rs and decreased 
release of dopamine. The cumulative activity during 30 minutes was also 
decreased in WT control mice after quinpirole administration as in the present 
study (Anzalone, et al 2012). However, the locomotor activity was increased by 
quinpirole in conditional D2 autoreceptor knockout mice and decreased more in 
conditional postsynaptic D2R knockout mice than in WT mice. Taken together, 
these studies suggest that quinpirole-induced hypolocomotion is an outcome of 
the activation of the D2 autoreceptors and the latter hyperactivation results from 
the increased release of dopamine and the activation of the postsynaptic 
dopamine receptors. This, in turn, suggests that the observed lack of stimulation 
in the H3R KO mice is regulated via mechanism involving the postsynaptic 
rather than the presynaptic receptors. As the quinpirole-induced inhibition of 
dopamine release diminishes in time, dopamine is subsequently released again 
in the second phase of its effect on locomotion. Thus, in the absence of D2R-
H3R heterodimer, it is assumed that the D2R affinity is increased which leads to 
potentiation of the inhibitory indirect dopaminergic pathway, further supporting 
the hypothesis that the complex D2R-H3R interaction occurs on the 
postsynaptic MSNs. 
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The same conditioning paradigm that was described earlier can be used to study 
CPA and the aversive effects of drugs. If the drug has negative motivational 
significance, mice will spend significantly less time in proximity to the drug-
associated cue, and can thus be considered aversive (Cunningham, et al 2006). 
In this thesis, we studied the effects of quinpirole on place conditioning in mice. 
The previous observations of quinpirole in place conditioning are controversial, 
ranging from no effect (Hoffman, et al 1988; Kivastik, et al 1996; Graham, et al 
2007) to significant place preference (Hoffman, et al 1988; White, et al 1991). 
However, we found that quinpirole induced a prominent place aversion in 
C57BL/6J mice. The contradictory results are possibly due to different doses of 
quinpirole used and methodological differences. In addition, the above-
mentioned studies were conducted using rats whereas in our experiments mice 
were used. Furthermore, as the quinpirole-induced hypolocomotion is likely due 
to inhibition of dopamine release via D2 autoreceptors (Bello, et al 2011) and 
the conditioning session lasted for 30 minutes, it is not surprising that 
quinpirole induced CPA rather than CPP. It would be interesting to test whether 
quinpirole induces CPP if mice were exposed to the conditioning environment 
during the hyperactive phase of quinpirole (after two hours of injection). Of 
importance, pretreatment with JNJ-39220675 neither increased nor decreased 
the aversive effect of quinpirole.  
 
In rats, repeated administration of quinpirole induces abrupt and long-lasting 
increase in the D2R sensitivity in a process called receptor priming (Einat and 
Szechtman 1993; Kostrzewa, et al 2004). D2R sensitization can be behaviorally 
detected as e.g. increased locomotor activity. Interestingly, increased D2R 
affinity and D2R sensitization have been suggested to play a role in the 
pathophysiology of psychiatric disorders such as schizophrenia and OCD 
(Seeman, et al 2006; Ducasse, et al 2014). In rat, quinpirole sensitization has 
also been used as a model for OCD (Szechtman, et al 1998; Perreault, et al 
2010; Tucci, et al 2014). We thus studied the locomotor responses of mice 
subjected to repeated administration of quinpirole. Furthermore, we investigated 
whether JNJ-39220675 has an effect on the behavioral outcome. After single 
administration, JNJ-39220675 did not modify the suppression of locomotion by 
quinpirole. The locomotor activity was followed for 30 minutes, and thus we 
could only detect the hypokinetic phase induced by quinpirole. Quinpirole was 
then administered on five consecutive days with or without the pretreatment 
with JNJ-39220675.  Interestingly, it was found that repeatedly administered 
quinpirole induced a pronounced tolerance to the acute hypolocomotion. The 
plausible explanations for this effect involve either sensitized postsynaptic 
D1Rs and/or D2Rs or desensitized D2 autoreceptors leading to increased 
release of dopamine. Moreover, JNJ-39220675 inhibited the tolerance that 
developed to quinpirole-evoked hypolocomotion, suggesting that H3R 
antagonism inhibits the behavioral responses of desensitized D2 autoreceptors 
or sensitized postsynaptic D2Rs. In other words, H3R antagonism seems to 
change the affinity of D2Rs as suggested previously. This gives further 
evidence of the interaction between H3Rs and D2Rs, which involves the 
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negative cross-talk between the postsynaptic H3Rs and D2Rs in the GABAergic 
MSNs leading to altered dopaminergic responsiveness. 
 
 
6.4  Histamine, H1R and H3R in sensorimotor gating (V) 
 
PPI is an operational measure of sensorimotor gating, in which the motor 
response to a sudden, intense stimulus is attenuated by a preceding, weaker, 
non-startling sensory stimulus (prepulse) (Graham 1975; Hoffman and Ison 
1980). PPI is considered to be a protective mechanism to buffer sensory 
processing and to prevent excessive information. In humans the protecting and 
facilitating effect of PPI on central information processing has been 
experimentally demonstrated (Foss, et al 1989; Foss, et al 1989). PPI is 
deficient in several psychiatric disorders including schizophrenia, OCD, HD 
and TS (Kohl, et al 2013; Swerdlow 2013). As the brain histaminergic system 
has been implicated in schizophrenia, HD and TS (Prell, et al 1995; Goodchild, 
et al 1999; Ercan-Sencicek, et al 2010), in this thesis we studied the PPI in 
different knockout mouse strains: HDC KO, H1R KO and H3R KO mice. 
 
In this thesis, we observed that H3R KO mice displayed normal responses to the 
startle stimulus, but interestingly the PPI responses were impaired. In HDC KO 
mice both startle and PPI responses were normal indicating that the altered PPI 
response in H3R KO mice occurs independently of histamine. The impairment 
of PPI in the H3R KO was restored by D2R antagonist haloperidol in both 
genotypes whereas the NMDA antagonist MK-801 impaired PPI in both 
genotypes. The higher response of H3R KO mice to haloperidol treatment 
suggests that H3R gene mutation has led to hypersensitivity of D2Rs. H3R KO 
mice were found to display similar acoustic startle responses as compared to the 
WT. In contrast, a previous study reported up to 2.5 times higher startle 
responses in H3R KO mice than in WT mice (Rizk, et al 2004). The 
controversy with the findings of the present study probably lies on the 
differences in the methodology. Rizk and colleagues kept the mice in isolation, 
did not habituate them to the startle measurement and played the acoustic 
stimuli in ascending order. In our experiments however, mice were group-
housed, habituated to the testing chamber and the startle stimuli were tested in a 
random order. Thus, the mice were possibly more anxious in the experiment by 
Rizk and colleagues (Rizk, et al 2004). The effects of H3R antagonists on PPI 
have also been tested in several previous studies, and the results have been 
controversial, probably due to differences both in methodology and mouse 
strains used. Ciproxifan, BF2.649, and ABT-239 did not improve the PPI 
impairment produced by apomorphine in rats (Burban, et al 2010). However, in 
DBA/2J mice ABT-239 significantly improved PPI in a dose-dependent 
manner. Furthermore, another study demonstrated that both thioperamide and 
ciproxifan enhanced PPI in DBA/2J mice, whereas in C57BL/6 mice the 
compound had no effect on PPI (Browman, et al 2004). These pharmacological 
models have suggested that H3R has a role in the modulation of PPI, but the 
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underlying mechanism is not known. As the neural circuits involved in the 
regulation of PPI are complex, involving e.g. the glutamatergic and 
dopaminergic systems (Li, et al 2009) it is not surprising that different H3R 
ligands display different behavioral responses, possibly due to different 
affinities to different H3R isoforms expressed heterogeneously in different 
brain regions.     
 
                                                          
 
6.5  Plausible mechanisms underlying the observed 
behaviors (I-V) 
 
Changes in alcohol metabolism and kinetics are unlikely to explain any of the 
findings observed in this thesis, as we found no differences in the plasma 
alcohol concentrations in between H3R antagonist vs. saline pretreated mice, 
H3R KO vs. WT mice or HDC KO vs. WT mice in response to alcohol 
treatment. Furthermore, no significant changes were detected in the dopamine 
and noradrenaline concentrations in the striatum and PFC between H3R KO and 
WT mice after 12 days access to alcohol. In agreement with our results, in drug-
naive H3R KO mice, the cortical levels of dopamine, noradrenaline and 
serotonin and their metabolites are comparable to those observed in WT mice 
(Toyota, et al 2002). However, significantly lower level of cortical histamine 
was observed in the H3R KO mice. This is unlikely to explain the results 
obtained in this thesis, and the possible mechanisms are discussed next.  
 
As expected from the behavioral experiments indicating that the lack of 
histamine does not result in major abnormalities in dopaminergic 
neurotransmission, no alterations in the expression of different dopaminergic 
signaling components in the striatum were observed in the HDC KO mice. 
However, H3R KO mice displayed lower levels of D1 receptor mRNA in the 
striatum whereas TH and DAT mRNA levels were similar in the VTA between 
control and H3R KO mice. This is in line with the hypothesis that H3R 
dependent modulation of dopaminergic functions involves an interaction with 
the dopamine receptors. 
 
Both D1R and D2R activation lead to phosphorylation of ERK1/2 and 
activation of its target substrates but also drugs of abuse regulate ERK1/2 
cascade in the MSNs of the striatum (Baik 2013). Our hypothesis was that both 
D1Rs and D2Rs interact with the H3Rs in vivo, and this might lead to 
diminished dopaminergic signaling, which in turn may alter behavioral 
responses such as alcohol reward and sensorimotor gating. The striatum and 
PFC were selected as target areas as they are involved in the circuits studied in 
this thesis. The importance of ERK1/2 and AKT in drug addiction including 
alcohol addiction have been studied extensively (Chen, et al 2009; Girault 
2012; Girault 2012; Baik 2013; Cahill, et al 2014) and were thus selected as 
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markers of dopaminergic activation. To specifically activate the dopaminergic 
system, we used D1R agonists SKF-38393 and D2R agonist quinpirole. 
Previous studies have shown that D2R activation by quinpirole activates 
ERK1/2 in D2R transfected cells (Wang, et al 2005), on brain slices (Yan, et al 
1999) and in striatal neurons (Cai, et al 2000; Brami-Cherrier, et al 2002). D1R 
activation by SKF-38393 has also been shown to induce phosphorylation of 
ERK1/2 in D1R transfected cells (Chen, et al 2004; Ferrada, et al 2009) and in 
rat striatal slices (Moreno, et al 2011). 
 
The existence of D1R-H3R heterodimers has been shown in mouse striatal 
slices, giving indirect evidence of their in vivo existence (Moreno, et al 2011). 
In the experiments of this thesis we took another approach as we wanted to 
study whether the dopaminergic signaling is also modulated by H3R when 
drugs are administered in vivo. Interestingly, we found that the dopaminergic 
signal transduction is altered in H3R KO mice after in vivo exposure to both 
SKF-38393 and quinpirole. This was observed by the semi-quantitative Western 
blotting in which we found that in H3R deficient mice neither SKF-38393 nor 
quinpirole activated ERK1/2 in the striatal tissue, although in the WT mice both 
compounds were found to phosphorylate ERK1/2 in the striatum. These ligands 
had no effect on ERK1/2 phosphorylation in the PFC, suggesting that the main 
location of action of these drugs is in the striatum. Taken together, these results 
support the previous findings obtained either with transfected cells or striatal 
sections. Of importance, our studies demonstrate that H3R is involved in the 
ERK1/2 signaling cascade in vivo and that both D1R and D2R signal 
transduction in the striatum is abnormal in the absence of H3Rs. 
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7. SUMMARY AND CONCLUSIONS  
 
 
The main findings of the present thesis and the conclusions that can be drawn 
from the results are the following: 
 
1. H3R KO mice are less sensitive to the stimulatory and motor-impairing 
effect of alcohol. In addition, both pharmacological blockade and 
genetic knockout of H3R lead to diminished alcohol consumption and 
reward.  
 
2. The lack of histamine per se does not alter alcohol consumption or 
reward. However, histamine is required for the H3R-mediated alcohol 
reward inhibition, which suggests that histamine has an inhibitory role 
in alcohol reward. 
 
3. Non-imidazole based H3R antagonist inhibits amphetamine-induced 
locomotor stimulation acutely and modifies D2R activation-mediated 
behavioral desensitization by quinpirole. However, H3R blockade does 
not modulate the rewarding effect of amphetamine or the aversive 
effect of quinpirole. 
 
4. The lack of H3R but not lack of histamine leads to impaired PPI 
indicating a deficiency in sensorimotor gating in H3R KO mice. This 
suggests that H3R might play a role in e.g. Tourette syndrome.  
 
5. The mechanism by which H3R regulates the above-described 
behavioral phenomena involves possibly the interaction between the 
striatal H3R and dopamine receptors. The interaction might occur on 
transcriptional level, suggested by the lower D1R mRNA expression in 
H3R KO mice, and on a signal transduction level, suggested by the lack 
of ERK1/2 activation in response to dopaminergic activation in H3R 
KO mice. 
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8. FUTURE PERSPECTIVES 
 
 
The behavioral data obtained in regard to alcohol-related behaviors indicated 
repeatedly and consistently that blockade of H3R leads to decreased alcohol 
consumption and diminishes alcohol reward in mice. One of the tested H3R 
antagonists used here, JNJ-39220675, has been clinically proven to be safe in 
humans. The preclinical results from this thesis and the concurrent work 
conducted in other research groups, encourages H3R antagonists to be tested in 
human alcoholics. Therefore, both preclinical and clinical studies on alcohol 
withdrawal and relapse should be conducted. If the results from those studies 
would be in line with the results obtained in this thesis, H3R antagonism might 
potentially be a novel approach to treat alcohol addiction. 
 
Here, we also studied whether H3R antagonism inhibits the rewarding 
properties of amphetamine, and contradictory to what we would in alcohol 
studies, found that neither of the tested doses of JNJ-39220675 had an effect on 
amphetamine reward. However, only one dose of amphetamine was tested 
which is why the results have to be interpreted carefully. In order to clarify the 
role of H3R antagonism in amphetamine reward other non-imidazole H3R 
antagonist and different doses of amphetamine should be tested. Additionally, 
both withdrawal and relapse studies should be conducted using H3R antagonists 
and amphetamine.  
 
These studies also raise the question whether H3R antagonist could be effective 
in diminishing the reward evoked by other drugs of abuse. As the majority of 
the role of H3R antagonist in drug addiction have been obtained using 
experimental, imidazole-based H3R ligands, their interpretation is difficult, if 
not impossible. Therefore, novel ligands should be tested in order to establish 
whether H3R antagonism inhibits self-administration and reward by other drugs 
of abuse such as cocaine, opioids and nicotine. 
 
Moreover, as the first H3R antagonist is soon entering the clinical use in the 
treatment of narcolepsy, it is tempting to consider other possible implications 
for H3R antagonists. We found here, that H3R antagonist modified the 
locomotor response of repeatedly administered quinpirole. Quinpirole-induced 
receptor sensitization and the following persistent compulsions have been used 
to model OCD. On this basis, it would be interesting to study whether H3R 
plays a role in animal models of OCD. 
 
We also showed that H3R KO mice display impaired sensorimotor gating, 
whereas contradictory to what others have published, the lack of histamine had 
no effect on sensorimotor gating. Thus, the role of histamine in sensorimotor 
gating remains unclear and should be further studied. Interestingly, this study 
also suggested that the D2R-mediated responses of the H3R KO are stronger 
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than those of control mice. Additionally, repeated administration of both JNJ-
39220675 and D2R agonist quinpirole led the altered response compared to that 
obtained with only repeatedly administrating quinpirole. Although these studies 
indicate that D2R-mediated behavioral responses are altered both in H3R KO 
mice and after H3R antagonist treatment, the mechanism remains to be studied. 
Furthermore, amphetamine-induced locomotor stimulation was increased in 
H3R KO mice and the stimulatory response evoked by repeated administration 
of JNJ-39220675 together with amphetamine was more sensitized than that 
obtained with amphetamine alone. This gives further support that H3R is an 
important regulator of dopaminergic functions. Investigations on cellular 
mechanisms, including protein-protein interaction, binding and signal 
transduction studies, would shed the light on the cross-talk between the H3Rs 
and dopamine receptors.  
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